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ABSTRACT  
     
Parkinson’s disease (PD) is a progressive neurodegenerative disorder, diagnosed late in 
the disease by a series of motor deficits that manifest over years or decades. It is characterized 
by degeneration of mid-brain dopaminergic neurons with a high prevalence of dementia 
associated with the spread of pathology to cortical regions. Patients exhibiting symptoms have 
already undergone significant neuronal loss without chance for recovery. Analysis of disease 
specific changes in gene expression directly from human patients can uncover invaluable clues 
about a still unknown etiology, the potential of which grows exponentially as additional gene 
regulatory measures are questioned. Epigenetic mechanisms are emerging as important 
components of neurodegeneration, including PD; the extent to which methylation changes 
correlate with disease progression has not yet been reported. This collection of work aims to 
define multiple layers of PD that will work toward developing biomarkers that not only could 
improve diagnostic accuracy, but also push the boundaries of the disease detection timeline. I 
examined changes in gene expression, alternative splicing of those gene products, and the 
regulatory mechanism of DNA methylation in the Parkinson’s disease system, as well as the 
pathologically related Alzheimer’s disease (AD). I first used RNA sequencing (RNAseq) to 
evaluate differential gene expression and alternative splicing in the posterior cingulate cortex of 
patients with PD and PD with dementia (PDD). Next, I performed a longitudinal genome-wide 
methylation study surveying ~850K CpG methylation sites in whole blood from 189 PD patients 
and 191 control individuals obtained at both a baseline and at a follow-up visit after 2 years. I also 
considered how symptom management medications could affect the regulatory mechanism of 
DNA methylation. In the last chapter of this work, I intersected RNAseq and DNA methylation 
array datasets from whole blood patient samples for integrated differential analyses of both PD 
and AD. Changes in gene expression and DNA methylation reveal clear patterns of pathway 
dysregulation that can be seen across brain and blood, from one study to the next. I present a 
thorough survey of molecular changes occurring within the idiopathic Parkinson’s disease patient 
and propose candidate targets for potential molecular biomarkers. 
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PREFACE 
This dissertation is the culminating collection of work initiated to study the molecular 
profiles of Parkinson’s disease (PD) patients with the overarching goal of impacting future 
biomarker development. The author completed this dissertation while in the Neurogenomics 
division of the Translational Genomics Research Institute (TGen), in coordination with Arizona 
State University (ASU). The mission of TGen is to produce research that can be translated to 
clinical applications, which drove the conceptualization of each of the studies contained here.  
The chapters in this dissertation where developed closely with Dr. Travis Dunckley. 
Leadership and study guidance where provided throughout by Drs. Dunckley and Matthew 
Huentelman. The author became involved in the first chapter’s work before beginning her PhD 
studies at ASU in 2014, completing and publishing the study shortly thereafter as first author. 
Chapter 2 was a collaborative effort divided between Drs. Dunckley and Paula Desplats of the 
University of California, San Diego (UCSD). The study was published in March 2019 with co-first 
authorship. Chapter 3 is a completed manuscript by the author and data analysis was performed 
almost entirely by the author. This will be submitted for publication as a first author work as well. 
All studies where efforts completed with the input and support from teams of people in the 
laboratories of Drs. Huentelman and Dunckley, and in the laboratory of Dr. Desplats for the work 
in chapter 2. 
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CHAPTER 1 
NEXT-GENERATION PROFILING TO IDENTIFY THE MOLECULAR ETIOLOGY OF 
PARKINSON'S DEMENTIA 
INTRODUCTION 
 Parkinson’s disease (PD) is the second most common neurologic disorder, characterized 
by degeneration of mid-brain dopaminergic neurons and a high prevalence of dementia. 
Neuroinflammation, oxidative stress, mitochondrial dysfunction, protein processing, and aberrant 
alternative splicing are among the commonly considered pathways of dysfunction in Parkinson’s 
disease(Cooper-Knock et al. 2012).  
 Gene expression profiling via microarrays has been a widely implemented and useful 
method for disease pathway elucidation, though its application is limited by the requirement for 
prior sequence information for probe design. The more recent development and use of next-
generation, high-throughput RNA sequencing (RNA-seq) has facilitated the expansion of gene 
expression knowledge by filling missing gene and isoform data gaps, in addition to reducing 
background noise and optimizing specificity by avoiding probe cross-hybridization(Mills and Janitz 
2012).  
 It is important to consider that microarrays are biased as they are limited by probe design 
and available gene annotations. For example, Loraine et al. identified at least 500 annotated 
pollen genes in their RNA-seq data that were not included on the ATH1 (Arabidopsis thaliana) 
microarray(Loraine et al. 2013). Even for extensively annotated genomes, microarrays lack 
complete sequence inclusion of 3’/5’ UTRs, introns, and alternative splice variants(Loraine et al. 
2013). More specific exon arrays have been successfully applied to alternative splicing 
studies(Shoemaker et al. 2001; Gardina et al. 2006; Moore and Silver 2008), but they remain 
insufficient for comprehensive novel splicing and isoform discovery. RNA-seq produces accurate, 
high resolution coverage of the transcriptome versus a probe-limited subset(Trapnell et al. 2013) 
and is currently the superior method for gene and isoform expression profiling for discovery, 
particularly when investigating the functions and effects of alternative splicing(Mills and Janitz 
2012; Nookaew et al. 2012; Sanchez-Pla et al. 2012; Giorgi et al. 2013; Loraine et al. 2013).  
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 Gene expression studies of PD and other neurological disorders, via microarray or RNA-
seq, have produced thematic results. Transcriptome microarray analysis of PD and controls 
showed that the PD-linked LRRK2 mutation is associated with expression changes in peripheral 
blood mononuclear cells (PBMCs)(Mutez et al. 2011). The same study highlighted alterations in 
the MAPK and GTPase pathways, which are involved in axonal guidance, actin cytoskeleton, and 
vesicular dynamics, among other functions. Evidence of downregulated synaptic genes (NSF, 
SYNGR3) and cytoskeletal maintenance genes (MARK1, MAP2, and DNAI1) in the substantia 
nigra suggest malfunction of cytoskeletal dynamics(Miller et al. 2006). In our previous microarray 
study, we found that axonal transport, cell adhesion, and mRNA splicing are the most prevalent 
dysregulated processes in PD. We also reported decreased expression in neurite outgrowth and 
cell adhesion proteins, all occurring prior to dementia onset(Stamper et al. 2008).  
 Since expression profiling provided evidence of significant spliceosome 
alterations(Stamper et al. 2008), in the present study we leveraged mRNA-seq to incorporate 
splice variant analysis. Analyses are restricted to coding RNAs, though non-coding and micro-
RNA (miRNA) studies offer good examples of how transcriptional changes are relevant on 
multiple levels(Minones-Moyano et al. 2011; Wood et al. 2013). Much attention has been given to 
overall expression changes between disease and controls, but we report here that differential 
alternative splicing is associated with PD and PD-dementia, possibly contributing to the etiology 
of these diseases. Alternative splicing of transcripts encoding components of immune response 
pathways and RNA processing correlate with disease states and the genes displaying the highest 
degree of alternative splicing in this dataset are somewhat disconnected from the greatest 
expression changes, though overlapping cellular processes are evident. Compared to gene 
expression profiling alone, alternative splice analysis of mRNA-seq data affords precision profiling 
in addition to an overview of global expression changes. 
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METHODS 
Tissue Collection  
 Posterior cingulate cortex samples were obtained from the Banner Sun Health Research 
Institute Brain Bank. All cases signed informed consent at Banner Sun Health Research Institute 
and were prospectively followed until death and autopsied according to previously published 
protocols(Beach et al. 2015). Samples were selected with a postmortem interval less than 3 
hours. Posterior cingulate cortex was sectioned at 8 μ  thickness and placed into standard 1.5 
mL microcentrifuge tubes and stored at -80°C until RNA extraction. 
RNA Extraction  
 TRIzol reagent (Life Tech) was added to each sample tube containing a fresh frozen 
brain tissue slice, then pipetted to homogenize. The solution was incubated at room temperature 
for 3 minutes followed by adding 100µl chloroform (Sigma). Tubes were hand-shaken for 15 
seconds and incubated at room temperature for 2 minutes then centrifuged at 12,000g for 15 
minutes at 4°C. The top aqueous layer was transferred into a new, cold microcentrifuge tube and 
1 equal volume cold 70% EtOH was added. The RNA solution was then processed through the 
Qiagen RNeasy Mini kit, with DNase treatment, using the manufacturer’s protocol. 
mRNAseq Library Preparation  
 1 µg of total RNA was used to generate mRNA-seq libraries for sequencing using 
Illumina’s RNA Sample Prep Kit (catalog#FC-122-1001) using the manufacturer’s protocol. In 
summary, poly-A selection was performed using oligo dT magnetic beads to capture mRNA 
transcripts, and double stranded cDNA was generated and fragmented to a target size of 400bp 
using sonication on the Covaris. Fragmented samples were then end repaired and adenylated at 
the 3’ end, and TruSeq Indexed adapters were ligated on. Libraries were enriched using the 
TruSeq PCR Master Mix and primer cocktail. Final libraries were cleaned and quantified using the 
Agilent Bioanalyzer and Invitrogen Qubit. Libraries were equimolarly pooled for sequencing. 
Paired-End Sequencing  
 Denatured and diluted libraries with a 1% phiX spike-in were used to generate clusters on 
Illumina’s HiSeq Paired End v3 flowcell on the Illumina cBot using Illumina’s TruSeq PE Cluster 
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Kit v3 (cat#PE-401-3001). The clustered flowcell was sequenced by synthesis on the Illumina 
HiSeq 2000 for paired 100bp reads using Illumina’s TruSeq SBS Kit V3 (cat#FC-401-3001). 
Sequencing and Differential Expression Analysis 
 An average of 109 million paired-end, passing-filter reads (90mers) were generated for 
each sample. Reads were trimmed of adapter sequences and aligned to H. sapiens GRCh37.62 
with TopHat (version 2.0.8, bowtie version 0.12.7) using default parameters. A table of read 
counts was assembled in R with the easyRNASeq package. Pairwise differential expression 
analyses between the groups was conducted with the DESeq package. 
Gene Ontology 
 GeneMANIA is a functional association tool used for data visualization and statistical 
analysis. It builds gene ontologies from gene input lists and is freely available as a web 
application (also available as a Cytoscape plugin); figures and tables are available for output 
organization. 
Alternative Splicing Analysis 
 SpliceSeq is an RNA-seq data visualization and statistical analysis tool. Comprehensive 
documentation is available from MD Anderson Bioinformatics, on the developer’s website. We 
used this program to investigate significant differential splicing events in disease groups (PD or 
PD-D) relative to controls. SpliceSeq returns gene RPKM and exon OPKM (Observations Per 
Kilobases of exon/splice per Million aligned reads) normalized read values, defined respectively 
as “Reads” and “Observations” per kilobase of transcript length per million aligned reads. OPKM 
provides a measure of exon expression; a read that contains at least 4 bases of an exon is 
“observed”.  
 Reads “spliced in”, i.e. reads that map to an exon, are calculated against the total of 
reads that span the flanking exons, but skip it, plus the spliced in reads. This is the “percent 
spliced in” (PSI) value assigned to each exon. The difference between the average exon PSI of 
“group 2” and “group 1” (e.g., PD minus CON) is termed delta PSI (dPSI).  
dPSI sample calculation: 
SRRM1 deltaPSI = PSI PD-D group – PSI CON group 
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 To obtain a log2 ratio of exon expression, OPKM values are measured against RPKMs 
(corrected for overall gene expression). The log2 ratio (mentioned in Figure 1) dictates whether an 
exon is highlighted as over-represented (green), under-represented (red), or normally 
represented (no highlight). 
qRT-PCR Validation 
 RNA extracted (described above) from PD, PD-D, and CON tissues was processed with 
the SuperScript III First-Strand Synthesis kit (Life Technologies) for cDNA synthesis, per the 
manufacturer’s protocol. qRT-PCR was completed using the Roche LightCycler 480 manufacturer 
protocol with their corresponding detection reagent, LightCycler 480 SYBR Green I Master.  
 Primer pairs for these regions were designed so that at least one primer site was situated 
within the spliced exon. Each primer set designed to cover a splice event was paired in the same 
gene with a primer set located in adjacent or nearby exons without predicted splicing activity. 
Placing primer sets in these two distinct areas served as a means to compare baseline 
expression levels without alternative splicing, to the alternative splice sites at which expression 
was predicted to vary. 
 
RESULTS 
 We performed mRNA-seq on RNA samples isolated from the posterior cingulate cortex 
(Brodmann Area 23) of individuals with either Parkinson’s disease (PD; N=13; mean age 79.3 
years +/- 6.8, 23% female), Parkinson’s disease with Dementia (PD-D; N=10; mean age 75.5 
years +/- 7.0, 30% female), or healthy controls (N=11; mean age 77.9 years +/- 7.9, 9% female)). 
Data analysis for this study focused on differential gene expression (DE) and alternative splicing 
(AS) events. DE and AS changes in PD and PD-D were quantified relative to unaffected controls. 
We utilized SpliceSeq(Ryan et al. 2012) for AS analysis, developed with RNA-seq data and 
alternative splicing detection in mind, and DESeq(Anders and Huber 2010) for DE analysis. 
=  11 11 + 11 ( )  
⎛
⎝⎜
⎞
⎠⎟
 –  27 10 + 27 ( )  
⎛
⎝⎜
⎞
⎠⎟
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Genes from DE and AS analyses were then compared for overlapping results and the data were 
run through GeneMANIA(Ashburner et al. 2000; Montojo et al. 2010), a web-based gene ontology 
(GO) program, to view common pathways or functions.  
Gene Ontology & Differential Expression. 
 We first compared gene-level expression profiles across disease groups (Table 1). DE 
lists were restricted to the top 20 genes differentially expressed by fold change (fc) ≥ |0.2| and p ≤ 
0.001 (multiple test-corrected with the Benjamini-Hochberg procedure), as determined by DESeq 
analysis. The top 20 DE genes from each group comparison were compared to gene networks for 
GO analysis(Montojo et al. 2010). Significant functions (Table 2) associated with the top 20 
overexpressed PD genes included cell chemotaxis, cytokine receptor binding, cAMP-mediated 
signaling, and ion homeostasis, while overexpressed PD-D genes were involved in unfolded or 
incorrectly folded protein responses. Underexpressed PD and PD-D genes shared a common 
involvement in hormone signaling. 
 Comparison of PD to control revealed changes in immune function and neuropeptide 
hormone function, including upregulation of chemokine (C-X-C motif) ligand 10 (CXCL10; p = 
1.78x10-16, fc = 15.845) and downregulation of proenkephalin (PENK; p = 5.73x10-8, fc = -3.355). 
In the comparison of PD-D to control, genes involved in the unfolded protein response were 
significantly upregulated, reflected by increased expression of dnaJ (Hsp40) homolog (DNAJB1; 
p = 3.16x10-8,fc = 3.876) and several heat-shock protein genes, and an overall downregulation of 
hormone activity and ion transport, indicated by decreased expression of corticotropin-releasing 
hormone (CRH; p = 6.4x10-7, fc = -4.724), PENK (p = 1.57x10-4, fc = -3.049), somatostatin (SST; 
p = 4.44x10-9, fc = -5.144), chemokine (C-C motif) ligand 3 (CCL3; p = 4.5x10-5, fc = -4.492) and 
chemokine (C-C motif) ligand 4 (CCL4; p = 9.47x10-7, fc = -8.737).  
 Predominant pathways shared by both PD and PD-D included upregulated inflammatory 
responses, with increased expression of granulocyte colony-stimulating factor (CSF3; pPD = 
8.25x10-19, fcPD = 9.920; pPD-D = 2.00x10-35, fcPD-D = 49.470), selectin-E (SELE; pPD = 4.24x10-12, 
fcPD = 4.808; pPD-D = 7.10x10-29, fcPD-D = 25.334), and additional cytokines. Shared downregulated 
genes for signaling and cytoskeletal structure were shown by decreased expression of PENK 
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(pPD = 5.73x10-8, fcPD = -3.355; pPD-D = 1.57x10-4, fcPD-D = -3.049) and keratin 5 (KRT5; pPD = 
1.47x10-7, fcPD = -4.718; pPD-D = 6.75x10-4, fcPD-D = -4.373); Vgf nerve growth factor (VGF; pPD = 
1.06x10-10, fcPD = -3.821; pPD-D = 1.61x10-8, fcPD-D = -5.621) was also downregulated across 
disease states.  
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A.  PD vs. CON Overexpressed  B.  PD vs. CON Underexpressed 
Gene P-value Fold Change 
 
Gene P-value Fold Change 
LMX1A 1.87 x 10-9 18.08 
 
FABP1 7.03 x 10-9 -9.14 
CXCL10 1.78 x 10-16 15.85 
 
HBG2 5.06 x 10-8 -6.97 
CSF3 8.25 x 10-19 9.92 
 
KRT5 1.47 x 10-7 -4.72 
S100A14 8.48 x 10-8 8.60 
 
(uncharacterized) 3.61 x 10-11 -4.50 
GRHL3 4.01 x 10-15 8.39 
 
FREM3 2.82 x 10-8 -4.04 
C6 1.14 x 10-13 6.44 
 
VGF 1.06 x 10-10 -3.82 
CHI3L2 2.59 x 10-8 5.86 
 
CNGB1 2.28 x 10-8 -3.71 
SELE 4.24 x 10-12 4.81 
 
FAM163A 6.90 x 10-8 -3.69 
CXCL11 1.29 x 10-8 4.50 
 
GLP2R 2.93 x 10-8 -3.41 
CD163 1.43 x 10-7 4.34 
 
CUX2 2.68 x 10-8 -3.38 
CCL2 6.90 x 10-8 4.33 
 
PENK 5.73 x 10-8 -3.35 
NTS 6.40 x 10-9 4.31 
 
SLC32A1 5.29 x 10-7 -3.29 
PZP 1.64 x 10-10 4.11 
 
PCDH8 7.57 x 10-9 -3.29 
SERPINA3 5.73 x 10-8 4.10 
 
SLC17A6 3.71 x 10-7 -3.27 
FCGR2B 2.82 x 10-8 4.08 
 
MEPE 3.73 x 10-7 -3.01 
RASSF9 7.70 x 10-9 3.68 
 
CALB2 1.57 x 10-8 -2.94 
CD44 6.97 x 10-8 3.59 
 
CBLN4 8.53 x 10-7 -2.86 
EMP1 4.59 x 10-8 3.52 
 
LAMP5 9.39 x 10-7 -2.84 
LTF 3.75 x 10-8 3.26 
 
CTXN3 2.25 x 10-7 -2.62 
TNC 1.69 x 10-7 3.16 
 
CARTPT 1.70 x 10-7 -2.16 
C.  PD-D vs. CON Overexpressed  D.  PD-D vs. CON Underexpressed 
Gene P-value Fold Change 
 
Gene P-value Fold Change 
CSF3 2.00 x 10-35 49.47 
 
C5orf17 6.95 x 10-4 -11.12 
SELE 7.10 x 10-29 25.33 
 
CCL4 9.47 x 10-7 -8.74 
SFN 1.00 x 10-10 14.27 
 
ACTG2 1.36 x 10-5 -6.52 
IGHG4 1.67 x 10-7 13.13 
 
DES 8.37 x 10-7 -6.32 
VHLL 4.76 x 10-6 10.28 
 
MYO1A 3.66 x 10-9 -5.66 
HSPA6 2.42 x 10-18 9.40 
 
VGF 1.61 x 10-8 -5.62 
IL8 9.70 x 10-17 9.00 
 
SST 4.44 x 10-9 -5.14 
IGHG1 4.59 x 10-9 8.31 
 
CRH 6.40 x 10-7 -4.72 
IL1R2 8.37 x 10-7 7.41 
 
CCL3 4.50 x 10-5 -4.49 
IGHG2 5.66 x 10-6 7.39 
 
KRT5 6.75 x 10-4 -4.37 
CXCR1 3.16 x 10-8 6.94 
 
HRNR 2.07 x 10-5 -4.12 
IGKC 1.90 x 10-6 6.33 
 
(uncharacterized) 1.13 x 10-3 -4.08 
IL6 2.10 x 10-10 5.94 
 
FAM216B 6.95 x 10-4 -3.60 
CXCL1 1.57 x 10-10 5.72 
 
ST8SIA2 1.13 x 10-3 -3.52 
NPC1L1 1.71 x 10-10 4.85 
 
DNAH3 1.38 x 10-3 -3.46 
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SERPINH1 1.83 x 10-8 4.24 
 
GPD1 3.47 x 10-4 -3.14 
DNAJB1 3.16 x 10-8 3.88 
 
PENK 1.57 x 10-4 -3.05 
HSPA1L 3.66 x 10-8 3.83 
 
PPEF1 1.77 x 10-3 -3.01 
HSPA1A 1.51 x 10-6 3.14 
 
HBA2 1.29 x 10-3 -2.54 
HSPA1B 2.30 x 10-6 3.08 
 
HBA1 1.60 x 10-3 -2.51 
 
A.  PD Overexpressed 
GO Function FDR 
Network  
Genes 
 Genome 
Genes 
cell chemotaxis 5.22 x 10-7 9 157 
cytokine receptor binding 5.60 x 10-6 8 147 
positive regulation of cAMP-mediated signaling 2.74 x 10-5 4 11 
chemokine receptor binding 2.74 x 10-5 5 32 
positive regulation of homeostatic process 1.04 x 10-4 5 46 
regulation of cAMP-mediated signaling 1.04 x 10-4 4 17 
positive regulation of release of sequestered calcium ion into cytosol 1.04 x 10-4 4 17 
metal ion homeostasis 2.72 x 10-4 8 288 
positive regulation of intracellular transport 3.87 x 10-4 6 122 
positive regulation of calcium ion transport into cytosol 4.40 x 10-4 4 26 
B.  PD Underexpressed 
GO Function FDR 
Network  
Genes 
 Genome 
Genes 
neuropeptide hormone activity 6.57 x 10-2 3 15 
hormone activity 9.19 x 10-1 3 44 
C.  PD-D Overexpressed 
GO Function FDR 
Network  
Genes 
 Genome 
Genes 
response to unfolded protein 3.66 x 10-18 14 106 
response to topologically incorrect protein 4.71 x 10-18 14 113 
protein folding 3.81 x 10-5 7 124 
cell chemotaxis 2.57 x 10-3 6 157 
COP9 signalosome 2.57 x 10-3 4 34 
cytokine receptor binding 2.57 x 10-3 6 147 
leukocyte chemotaxis 6.76 x 10-3 5 106 
blood microparticle 6.76 x 10-3 5 108 
unfolded protein binding 8.52 x 10-3 4 52 
defense response to Gram-negative bacterium 8.73 x 10-3 3 16 
D.  PD-D Underexpressed 
GO Function FDR 
Network  
Genes 
 Genome 
Genes 
Table 1. PD over- (A) and underexpressed (B) genes and PD-D over- (C) and 
underexpressed (D) genes make up the lists used for GO analysis (p ≤ 0.001, fc ≥ |0.2|). 
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neuropeptide hormone activity 3.04 x 10-2 3 15 
hormone activity 3.04 x 10-2 4 44 
calcium-mediated signaling 7.66 x 10-2 4 72 
bicarbonate transport 1.20 x 10-1 3 29 
regulation of system process 1.78 x 10-1 5 203 
blood microparticle 1.90 x 10-1 4 108 
second-messenger-mediated signaling 2.78 x 10-1 4 124 
gas transport 4.05 x 10-1 2 10 
hydrogen peroxide catabolic process 4.08 x 10-1 2 14 
cellular ion homeostasis 4.08 x 10-1 5 292 
 
Alternative Splicing. 
 SpliceSeq identified significant disease-associated differences in transcript variants. To 
make predictions of alternative splicing events, SpliceSeq builds a “splice graph” based on 
current Ensembl transcript isoform data to which it aligns experimental transcript data for each 
sample, followed by normalization and statistical calculations (see Methods). User-defined groups 
can then be compared for expression differences. In this case, “groups” are defined by patient 
category, either PD, PD-D, or control (CON). SpliceSeq-predicted events were initially filtered for 
significance (p < 0.01) and dPSI > |0.2|, where dPSI (or “differential percent spliced in”) is the 
change in exon expression of disease vs. controls. Additional filtering parameters considered the 
occurrence of the splicing event across all transcripts in the group (magnitude) and the number of 
samples within the group experiencing the event (percent observed)– both set to > |0.8| (1.0 = 
100%). Finally, genes with the highest reads per kilobase of transcript length per million aligned 
reads (RPKM) within the filtered lists (15-100 RPKM) were preferentially picked for validation 
(Table 3).  
 Transcription factors, in concert with immune responses and indicators of cellular stress 
and RNA processing, were among the most highly alternatively spliced mRNAs. Five genes (total 
= 40) from the PD-D/CON comparison (ATXN2, DST, HSPH1, RELA, SRRM1) and two genes 
Table 2. GeneMANIA measures significance by false discovery rate (FDR). Numbers of 
genes involved in a particular cellular function are shown, both within the resulting network 
and from the entire genome. The first 10 functions (of 87) are listed from overexpressed PD 
genes, and the first 10 (of 56) from overexpressed PD-D genes (A,C). All functions from 
underexpressed genes are shown (B,D). 
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(total = 10) from the PD/CON comparison (LRRFIP1, TRIM9) were chosen for qRT-PCR 
validation of the specific AS events (Figure 1). Heat shock protein 105 kDa (HSPH1), rel-like 
domain-containing (RELA), leucine-rich repeat flightless-interacting protein 1 (LRRFIP1), and 
tripartite motif 9 (TRIM9) may be grouped by processes of cellular maintenance or stress 
response (proliferation, apoptosis, etc.), and immune responses. RELA, LRRFIP1, and TRIM9 
are also transcription factors. Ataxin-2 (ATXN2) and serine/arginine repetitive matrix 1 (SRRM1) 
perform RNA processing functions. Dystonin (DST) is a cytoskeletal linking protein.  
We performed qRT-PCR on exons predicted by SpliceSeq to experience an event, either 
exclusion from, or inclusion in the final transcript (see Table 4 for exon sites and primer 
sequences). SpliceSeq-predicted exon level expression changes (Figure 2) were validated by 
comparison to qRT-PCR fold changes (“fc”; 2-e pe). Significant fold change values less than one 
for primers covering exon skip regions, and greater than one for the exon inclusion event, were 
considered validated. 
 In PD-D, skips were predicted by SpliceSeq at ATXN2 exon 21 (dPSI= -0.255, fc= 0.674), 
DST exon 104 (dPSI= -0.255, fc= 1.160), HSPH1 exon 13 (dPSI= -0.231, fc= 0.952), and SRRM1 
exon 16, which disrupts a region reported as necessary for speckles and matrix localization 
(dPSI= -0.250, fc= 0.598). Exon 10.2 of RELA was predicted to be spliced in (dPSI= 0.286, fc= 
3.467). This is a 687bp inclusion containing a premature stop site that would result in a 377 
amino acid (AA) truncated isoform, from the wild-type 551 AA isoform, and consequently 
eliminate an activation domain.  
In PD, skips were predicted in LRRFIP1 exons 18-19 within a coiled-coil structural region (dPSI= 
-0.257, fc= 0.821) and TRIM9 exons 8-10 within a fibronectin type III and B30.2/SPRY domain 
(dPSI= -0.264, fc= 0.930). 
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PD-D 
Gene (exon #) P-Value dPSI Magnitude % Observed RPKMCON RPKMPD-D 
ATXN2 (21) 7.81 x 10-3 -0.231 1.000 100% 15.9 14.0 
DST (104) 3.21 x 10-3 -0.255 1.000 100% 81.4 85.6 
HSPH1 (13) 9.50 x 10-3 -0.231 0.962 100% 48.8 99.6 
RELA (10.2) 5.09 x 10-4 0.286 0.978 100% 16.1 24.9 
SRRM1 (16) 4.95 x 10-3 -0.250 0.994 100% 34.2 25.6 
PD 
Gene (exon #) P-Value dPSI Magnitude % Observed RPKMCON RPKMPD 
LRRFIP1 (18-19) 8.76 x 10-3 -0.257 1.000 100% 12.5 8.7 
TRIM9 (8-10) 1.83 x 10-3 -0.264 0.932 100% 22.9 22.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. SpliceSeq-predicted Event Statistics for Genes to be Validated by qRT-PCR. Top 
alternatively spliced genes obtained by filtering for p < 0.01, dPSI > |0.2|, magnitude and % 
observed > |0.8| (1.0 = 100%). The resulting lists contained 40 PD-D genes and 10 PD genes. 
Finally, genes with the highest RPKM values were chosen for validation by qRT-PCR. 
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Fig 1. SpliceSeq “splice graphs” for the seven qRT-PCR tested genes. RNA-seq transcript 
reads are aligned to composite gene graphs built from all possible isoforms existing in the 
Ensembl genome database. The graphs in this figure are partial splice graphs, replicated from 
the SpliceSeq software, to show the alternative splicing regions discussed in this paper. 
Values on graphs are splice OPKMs, but can be changed in SpliceSeq to display read counts 
or log2 ratios (see Methods for explanation of terms). Exon highlighting indicates up- or down-
regulated exon expression or splicing as follows:  green exons and splice arcs represent 
increased activity in the control group and red exons and splice arcs represent either the PD 
or PD-D disease group. Gene splice graphs shown are specific for PD-D vs. CON (ATXN2, 
DST, HSPH1, RELA, SRRM1) or PD vs. CON (LRRFIP1, TRIM9). 
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qRT-PCR. 
 Fold changes of the predicted alternative splice sites (fcas) were compared to fold 
changes of adjacent sites lacking any predicted splicing activity, referred to as “no-splice” (fcns). 
Six of the seven genes were predicted to have exon skips, and one, an exon inclusion (RELA).  
 PD-D specific alternative splicing. At splice-predicted sites of ATXN2 (fcas= 0.674, fcns= 
2.201), HSPH1(fcas= 0.952, fcns= 1.924), and SRRM1 (fcas= 0.598, fcns= 0.780), fold changes 
were less than 1 relative to controls, in addition to having reduced expression compared to sites 
without predicted splice events. This is consistent with exon exclusion events in these transcripts. 
RELA (fcas= 3.467, fcns= 1.323), at the predicted inclusion site, was greater than 1 and 
Table 4. Splicing events and qRT-PCR primer sequences. 
Fig 2. dPSI values for SpliceSeq-predicted alternatively spliced exons within the 
labeled genes. Exon dPSI represents the difference in percent spliced in, disease 
vs. controls (see Table 3 for exon details). 
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overexpressed relative to the no-splice site. This indicates specific inclusion of exon 10.2. A 
change in DST was indiscernible from controls and its no-splice site (fcas= 1.160, fcns= 1.171). 
 PD specific alternative splicing. LRRFIP1 (fcas= 0.794, fcns= 1.075) and TRIM9 (fcas= 
0.667, fcns= 0.936) fc values (<1) likewise indicate reduced exon expression of the predicted exon 
for each gene. Figure 3 summarizes these results by comparing the fold change of alternatively 
spliced transcripts (fcas) to the main transcript isoforms (no-splice (fcns)) as expression ratios, 
represented by percent exon inclusion of the alternative splice site. Exon skips are less than 
100%, while the inclusion is greater than 100%. Results demonstrate that the vast majority of 
predicted AS events selected for validation were confirmed by secondary qRT-PCR measures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. qRT-PCR disease vs. controls fold change comparison of splice vs. 
no-splice primer sites. 
Exon regions with expected alternative splicing activity are compared to flanking 
exon regions without predicted alternative splicing, "no-splice". The dotted line 
indicates 100% inclusion (of a queried exon). 
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DISCUSSION 
 We present an mRNA-seq reference dataset to further characterize the molecular 
etiology of PD and PD-D. In addition to significant gene level differential mRNA expression, RNA-
seq clearly reveals underlying differential alternative splicing in the posterior cingulate cortex 
during the course of PD and PD-D. Alternative splicing of ATXN2, HSPH1, SRRM1, RELA, 
LRRFIP1, and TRIM9 suggest dysregulation of genes within immune and inflammation 
responses, as well as transcription and RNA processing. Compared to this alternative splicing 
profile, genes among those that were the most significantly differentially expressed (CSF3, SELE, 
PENK, VGF, KRT5, CRH, and SST) illustrate the breadth of PD gene dysregulation, beyond one 
level of expression analysis. In overall expression changes, immune activity is prominent, but 
there is also evidence of disrupted neuronal signaling pathways.  
Differential Gene Expression. 
 Overexpressed in both PD and PD-D relative to controls: CSF3 and SELE. One 
proposed contributing mechanism to PD etiology has been dysregulation of the immune system. 
Upregulation of both Granulocyte colony-stimulating factor (CSF3; pPD = 8.25x10-19, fcPD = 9.920; 
pPD-D = 2.00x10-35, fcPD-D = 49.470) and Selectin-E (SELE; pPD = 4.24x10-12, fcPD = 4.808; pPD-D = 
7.10x10-29, fcPD-D = 25.334) in PD patients, prior to significant pathology in the posterior cingulate 
cortex, is consistent with an early role of immune induction in the progression of PD.  
 CSF3 (or G-CSF) is one of three major CSFs, distinguished for its granulocyte 
involvement in differentiation and apoptosis inhibition(Schneider et al. 2005). It is a major cytokine 
regulator of neutrophils, and promotes their increased production in bone marrow(Panopoulos 
and Watowich 2008; Fife et al. 2009). Due to its immune functions, normal CSF3 levels in healthy 
individuals are relatively low and increase greatly under disease state. Pharmacological 
administration of G-CSF has been used as an immunotherapy to expedite and maintain the 
natural immune response and its receptors have been found in hematopoietic and non-
hematopoietic cells, including in central nervous system (CNS) neurons and adult neural stem 
cells(Panopoulos and Watowich 2008). Comparable to their immune system role of promoting 
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neutrophil production by stem cell differentiation, CSF3 can induce neuronal differentiation from 
adult progenitor cells while also protecting neurons from apoptosis(Schneider et al. 2005). 
 SELE is a cell adhesion molecule (CAM) that aids leukocytes in attaching to the 
endothelium; monocyte CAMs are activated in neurodegeneration(Hochstrasser et al. 2010). 
Elevation of serum SELE has been detected in Guillain-Barre syndrome and MS, but when 
investigated in Alzheimer’s disease patients, levels did not differ(Rentzos et al. 2005). To our 
knowledge, this is the first report showing induction in cortex of PD patients. 
 Underexpressed in both PD and PD-D relative to controls: PENK, VGF, and KRT5. 
Underexpressed genes in both PD and PD-D suggest potential deficits in neurotransmitter 
signaling and altered cytoskeletal function. 
 Proenkephalin (PENK; pPD = 5.73x10-8, fcPD = -3.355; pPD-D = 1.57x10-4, fcPD-D = -3.049) is 
a precursor protein of signal peptides that function as neurotransmitters, autocrine and paracrine 
factors, and hormones(Denning et al. 2008). Consistent with our expression results, Backman et 
al report evidence of significant down-regulation, relative to young controls (mean age 31), in both 
aging controls (mean age 77) and PD patients(Backman et al. 2007). PENK is also linked to 
bipolar disorder(Altar et al. 2009). 
 Vgf nerve growth factor (VGF; pPD = 1.06x10-10, fcPD = -3.821; pPD-D = 1.61x10-8, fcPD-D = -
5.621) is a neurosecretory protein most often expressed in neuroendocrine cells and 
neurons(Ferri et al. 2011). It has been studied and targeted as a promising disease biomarker 
due to reduced expression in cerebrospinal fluid (CF) for both AD and ALS patients (Zhao et al. 
2008; Jahn et al. 2011); expression in parietal cortex is reportedly reduced in PD(Cocco et al. 
2010). Ferri et al. support VGF as a biomarker of neurodegenerative and other diseases for its 
differential CF expression and cell type specific profiles within neuroendocrine organs(Ferri et al. 
2011). 
 Keratin 5 (KRT5; pPD = 1.47x10-7, fcPD = -4.718; pPD-D = 6.75x10-4, fcPD-D = -4.373) 
encodes a major keratin of the basal cell layer as part of the intermediate filament cytoskeleton in 
basal keratinocytes(Betz et al. 2006; Chamcheu et al. 2011). Epidermolysis bullosa simplex 
causes intraepidermal blistering and is caused in part by a KRT5 mutation(Chamcheu et al. 
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2011). Keratins are likely necessary for cell adhesion organization, organelle transport and 
nuclear anchorage(Betz et al. 2006). 
 Underexpression unique to PD-D: CRH and SST. Downregulation of certain hormone 
proteins suggest a potential hormone imbalance associated with dementia onset. Corticotropin-
releasing hormone (CRH; p = 6.4x10-7, fc = -4.724) and somatostatin (SST; p = 4.44x10-9, fc = -
5.144) are underexpressed, as well as PENK (1.57x10-4, fc = -3.049), all of which are indicated by 
gene ontology to be involved with an altered hormone signaling state.  
 CRH is released along the stress response pathway by the hypothalamus and acts on 
the pituitary to release adrenocorticotropin (ACTH) to subsequently release a corticosteroid like 
cortisol(Bao et al. 2008). 
 SST (or SRIF, somatotrophin-release-inhibitory factor) is a neurotransmitter and a 
neuromodulator(Lu and Stoessl 2002). Exogenous expression may increase neuronal dopamine 
release and modulate dopamine-dependent behavior(Ionov and Pushinskaya 2013). 
Alternatively Spliced Genes. 
 The genes that emerged from alternative splicing analyses did not exhibit a high degree 
of differential expression when assessed at the gene level. Nor did these genes clearly overlap 
with the top differentially expressed genes, although they often function in overlapping pathways. 
However, within the AS group, there are a variety of overlapping functions or instances of close 
networking. 
 Tripartite motif (TRIM) proteins belong to a subgroup of RING finger proteins, a structural 
feature that functions as a ubiquitin ligase (E3) to conjugate ubiquitin to target proteins; some 
TRIMs are important within innate and adaptive immune pathways(Tanji et al. 2010; Shi et al. 
2014). TRIM9 is thought to be a targeting signal for proteasomal degradation, may be involved in 
neuron development and synaptic vesicle exocytosis, and is a negative regulator of transcription 
factor NF-κB activation(Short and Cox 2006; Tanji et al. 2010; Shi et al. 2014). It has been found 
in Lewy Bodies (LB) of both dementia with LBs (DLB) and PD; expression is decreased in DLB 
and rabies virus infected brains, another case in which degeneration occurs(Tanji et al. 2010). 
Skipping of exons 8-10 approaching the C-terminus (protein position 550-636; dPSI = -0.264), 
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shown in our data, affects a fibronectin type III and B30.2/SPRY domain. This domain is 
associated with microtubule binding among the RBCC (N-terminal RING finger/B-box/coiled coil) 
protein family, to which TRIM9 and many other TRIM proteins belong. Mutations in the C-terminal 
B30.2-like domain of another RBCC protein, MID1, disrupts localization and ubiquitin 
targeting(Short and Cox 2006). 
 p65 protein is encoded by RELA (rel-like domain-containing protein) and is a subunit of 
the NF-κB transcription factor complex. They are part of a family of proteins involved in immune 
and inflammatory responses, apoptosis, and cell proliferation and differentiation(Huang et al. 
2009). NF-κB nuclear localization, from the cytosol, is inhibited by IκB association with the p50-
p65 heterodimer, which is liberated upon phosphorylation of IκB(Sharif-Askari et al. 2010). 
Though both TRIM9 and p65 interact with the NF-κB pathway, it has been shown that TRIM9 
affects activation steps subsequent to the activation steps directed on p65(Shi et al. 2014). Of the 
splicing activity predicted and validated here, the exon inclusion (exon 10.2, protein position 347-
381; dPSI = 0.286) within RELA leading to a possible protein truncation, with an activation 
domain deletion, is presumably the most detrimental alteration, predicted to cause overproduction 
of a truncated, inactive form of the protein. 
Heat shock proteins (HSP) are molecular chaperones that assist in protein folding or degradation, 
ER stress response regulation and steps in the apoptosis cascade(Meares et al. 2008). HSPH1, 
a 105 kDa HSP (HSP105), directs caspase-3 mediated apoptosis following ER stress, and 
interacts with α-tubulin to suppress disorganization during heat shock(Saito et al. 2003; Meares et 
al. 2008). HSP105β is a truncated isoform (92 kDa) induced specifically at 42°C, not by other 
stressors(Ishihara et al. 1999). Our data shows a skip (exon 13, protein position 529-572; dPSI = 
-0.231), elevated in PD-D compared to controls, consistent with this β isoform. Normal 
physiological temperature ranges from peripheral 33°C to fever-induced 39°C and does not reach 
the extreme temperature (42°C) associated with a heat shock response(Katkere et al. 2010). If 
the high-heat responding β isoform is overproduced instead of the constitutively active form, 
signaling for apoptosis could be dampened as a result of reduced functional activity within the 
normal physiological temperature range. 
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 Serine/arginine repetitive matrix 1, SRm160 (or SRRM1, SR-related matrix protein of 160 
kD), is a pre-mRNA splicing co-activator that associates with the nuclear matrix along with its 
binding partner SRm300, aiding in recruitment of splicing factors to speckled regions and 
assembly of complexes; SRm160 may also be involved in mature mRNA transport within the 
space of the nucleus(Blencowe et al. 1998; Wagner et al. 2003). Disruption to a sequence portion 
that is necessary for speckle and matrix localization, both structures at which pre-mRNA splicing 
is shown to occur within the nucleus, could hinder recruitment of pre-mRNA to these areas and 
therefore disrupt proper splicing and processing to mature mRNA. In the PD-D patients, exon 16 
(protein position 558-570; dPSI = -0.250), which is within the region encoding speckles and 
matrix localization specificity, is preferentially included in the mature mRNA. 
 Ataxin-2 is an RNA binding protein involved in RNA processing and endocytosis, 
impacting membrane receptor presence. In vivo knockout of the mouse homologue SCA2 leads 
to increased insulin production with a concurrent reduction in insulin receptors, resulting in 
obesity. ATXN2 also associates with EGFR (epidermal growth factor) in endocytic 
trafficking(Nonis et al. 2008), a process linked with huntingtin and parkin genes implicated in 
Huntington’s and Parkinson’s diseases, respectively. Exclusion of exon 21 (protein position 1127-
1145; dPSI = -0.231), as reported here, was also previously identified by a broad sequencing and 
characterization study, though the effect of this particular event is unknown. While a poly-Q 
expansion within ATXN2 is a notorious culprit of genetic malfunction, the exon 21 skip discussed 
here is far downstream (>2Kbp) from the well-studied region in exon 1. Similar to the 
aforementioned mouse study, alternatively spliced ATXN2 might interfere with cellular responses 
by reducing receptor production or membrane incorporation. However, the specific functional 
effect of this alternative splicing event is unclear. 
 Leucine-rich repeat flightless-interacting protein 1 is a promoter-binding transcriptional 
repressor that imposes regulatory control on EGFR, and also associates with the platelet 
cytoskeleton during clot formation(Rikiyama et al. 2003; Goodall et al. 2010; Alkelai et al. 2011). 
LRRFIP1 also may regulate the proinflammatory cytokine TNF and is a component of the TNFR 
superfamily(Alkelai et al. 2011; Li et al. 2014). These functions suggest LRRFIP1 is closely tied to 
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cell damage and injury response. Exons 18 and 19 (protein position 398-459; dPSI = -0.257) 
skipping were increased in our PD group. Together, they partially encode coiled-coil domains and 
a prefoldin superfamily domain, protein features that promote protein-protein interactions and 
molecular chaperoning, respectively(Siegert et al. 2000; Rikiyama et al. 2003). Exon skipping in 
this region has the potential to decrease binding affinity with LRRFIP1 targets and to interrupt any 
chaperone activity this protein may provide. Ontological query shows that other proteins with the 
prefoldin domain tend to be involved with protein folding and cytoskeletal binding. Therefore, this 
particular domain might influence the interaction of LFFRIP1 with the cytoskeleton. 
The Potential Roles of Alternative Splicing in PD. 
 Though alternative splicing is a normal mechanism of expression alteration and control, 
the pathways in which it is relatively increased suggest the most active responses in the disease 
state. Analysis of alternative splicing can reveal aberrant splicing of key disease genes. A number 
of scenarios are possible. An aberrantly spliced transcript may drive a pathway to become 
overactive, contributing to disease onset or progression. Another possibility is that cells in distress 
during the progression of PD and PD-D may experience altered splicing as a consequence of 
widespread dysfunction. Distinguishing between these possibilities is an important goal of future 
work. 
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CHAPTER 2 
DNA METHYLATION CHANGES ASSOCIATED WITH PARKINSON’S DISEASE 
PROGRESSION: OUTCOMES FROM THE FIRST LONGITUDINAL GENOME-WIDE METHY 
INTRODUCTION 
 
Parkinson disease (PD) is the second most common neurodegenerative disorder of the 
elderly, currently affecting~2% of the population over 60 years of age(Dauer and Przedborski 
2003). PD presents clinically as a progressive movement disorder with resting tremor and 
postural instability; and it is characterized neuropathologically by intracytoplasmic α-synuclein (α-
syn) aggregates in Lewy bodies (Spillantini et al. 1997). Neurodegeneration occurs primarily in 
dopaminergic neurons of the substantia nigra, but Lewy body pathology occurs in limbic and 
cortical areas as PD progresses (Mattila et al. 2000).   
PD is a multifactorial disease where environmental and genetic factors are intricately 
associated. In idiopathic PD, 60-70% of dopaminergic neurons have already been lost by the time 
someone presents clinical symptoms sufficient for a diagnosis (Ferrer et al. 2011b). Multiple pre-
motor biomarkers are actively being investigated for their potential to identify early-stage PD or 
patients at risk for developing PD (Haas et al. 2012), including clinical measures (rapid eye 
movement behavior disorder (RBD), olfactory deficits, mood disorders); molecular measures (α-
syn in cerebrospinal fluid and blood); and brain imaging.  
Epigenetic mechanisms are emerging as important factors in the molecular etiology of 
neurodegenerative diseases, including PD (Pavlou and Outeiro 2017). Hypomethylation of the α-
synuclein gene (SNCA) promoter region has been reported in substantia nigra of PD 
patients(Jowaed et al. 2010; Matsumoto et al. 2010). Moreover, this SNCA promoter 
hypomethylation has been shown to increase SNCA protein expression in cell culture, possibly 
contributing to the pathology of PD. Interestingly, L-dopa therapy has been associated with 
hypermethylation of the SNCA promoter, suggesting that current PD therapy may alter 
methylation (Schmitt et al. 2015). While results on altered SNCA methylation in PD have not been 
replicated by other studies using smaller cohorts (Richter et al. 2012; Guhathakurta et al. 2017); 
epigenomic changes associated with other genes including hypomethylation of NPAS2(Lin et al. 
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2012) and CYP2E1(Kaut et al. 2012);  and hypermethylation of PGC1-d(Su et al. 2015) and the 
H1 haplotype of Tau (MAPT)(Coupland et al. 2014), have also been implicated in PD. 
We previously demonstrated alterations in the intracellular localization of DNA 
methyltransferase 1 (DNMT1), which catalyzes the addition of methyl groups to the DNA, and that 
appeared retained in the cytoplasm in neurons from PD patients (Desplats et al. 2011), due to 
interaction with misfolded α-syn. These observations provided a potential mechanistic 
explanation for the hypomethylation of multiple genes in PD and suggested global alterations in 
the methylome of PD patients. Indeed, we subsequently identified methylation changes in brain 
and blood samples from PD cases in comparison to control subjects in a pilot study using a small 
cohort. Notably, we identified concordant methylation changes in matching brain and blood 
samples, thus supporting the idea that blood may serve as a surrogate tissue for brain 
methylation analyses in PD(Masliah et al. 2013). Subsequently, Moore et al.(Moore et al. 2014) 
reported a subset of CpG sites with altered methylation in PD and confirmed two CpG sites via 
bisulfite sequencing in a second cohort of 219 PD patients versus 223 control individuals. Most 
recently, an epigenome-wide association study (EWAS) using 335 PD and 237 control blood DNA 
samples identified 82 CpG sites of altered DNA methylation in PD patients, also using the 
previous generation Infinium 450K HumanMethylation beadchip(Chuang et al. 2017). 
These studies provide indications that there are significant alterations to the methylome 
of PD patients in both brain and blood tissues. Noteworthy, these previous studies were based on 
single-time point samples, hindering the observation of potential epigenomic changes associated 
with disease progression. Here we report results of the first longitudinal analysis of genome-wide 
methylation surveying over 850,000 CpG sites in 189 PD patients and 191 controls enrolled in the 
Harvard Biomarkers Study at both baseline and a follow-up visit that was ~2 years later. We 
present evidence of specific methylation changes associated with PD status, disease 
progression, and PD medication. 
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MATERIALS AND METHODS 
 
Study cohort 
 This longitudinal case-control study is nested within the Harvard Biomarkers Study (HBS) 
(Ding et al. 2013; Locascio et al. 2015; Liu et al. 2016; Liu et al. 2017). The HBS is an ongoing 
case-control study including individuals with PD, Alzheimer’s disease, and controls without 
neurologic disease, and collecting high-quality biosamples and high-resolution clinical 
phenotypes longitudinally over a five-year period (under funding from the Harvard 
NeuroDiscovery Center). Clinical characteristics of patients with PD enrolled in HBS that were 
selected for this study are shown in Table 5. Individuals with early-stage PD and controls (CT) 
were enrolled into HBS from Massachusetts General Hospital and Brigham & Women’s Hospital. 
Inclusion criteria for cases with PD were age ≥ 21; diagnosis of PD according to UK brain bank 
criteria; MMSE score > 21. Main exclusion criteria for cases with PD were diagnosis of a blood or 
bleeding disorder, known hematocrit < 30. Cases for the nested longitudinal case-control 
methylation study were selected from the HBS population based on additional criteria that 
included the availability of follow-up visit(s), age ≥ 55, baseline Hoehn and Yahr stage ≤ 3, 
baseline MMSE > 27. Sex-matched and age-similar controls were selected who had a baseline 
MMSE > 27 and available follow-up visit(s). Cases and controls with a past medical history of 
cancer (that might affect methylation status) were excluded. To increase diagnostic certainty, 
subjects with a diagnosis change on longitudinal follow-up were excluded from the current study. 
Familial PD cases carrying a G2019S LRRK2 mutation were also excluded.  
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Phenotype PD Control 
Female/Male  59/130 64/127 
Age at baseline visit 1 67.31 (6.95)/68.08 (7.05) 66.83 (2.63)/ 70.89 (6.16) *** 
Age at follow-up visit  69.58 (7.34)/70.33 (7.05) 69.05 (2.54)/ 72.98 (6.03) ** 
Education at baseline 2  15.25 (1.57)/15.22 (1.93) 15.63 (1.18)/14.98 (2.07) 
Ever Smoked  27/53 20/37 
Current Smoker (baseline) 1/0 2/5 
Current Smoker (follow-up) 1/0 2/5 
Disease Duration at baseline 3 3.73 (3.99)/3.72 (3.97)   
HY 4 (baseline)  2.00 (0.48) / 2.01 (0.42)    
HY (follow-up) 2.33 (0.60) / 2.20 (0.42) ***   
t-test HY 5  0.001717/0.0005481   
MMSE 6 (baseline) 29.02 (1.03)/ 28.98 (1.08) 29.26 (0.92) / 28.84 (1.17)  
MMSE (follow-up) 28.71 (1.95)/ 28.73 (1.61)  29.22 (1.24) /28.96 (1.27) 
WBC 7 (baseline) 6.28 (1.33) / 6.70 (1.59)  6.11 (1.53) / 6.41 (1.75)  
WBC (follow-up) 6.48 (1.54) / 6.54 (1.55)  6.15 (1.71) / 6.40 (1.65)  
RBC 8 (baseline) 4.56 (1.23) / 4.70 (0.42)  4.45 (0.34) / 4.75 (0.42)  
RBC (follow-up) 4.37 (0.39) /4.58 (0.52)  4.44 (0.36) / 4.69 (0.42)  
De novo 9 (baseline) 5/14   
De novo (follow-up) 1/2   
on medication10 (baseline) 38/82   
on medication (follow-up) 50/108   
 
 
Array Processing 
 Genomic DNA (1µg) samples received from HBS were coded and randomized with 
respect to disease status. DNA was bisulfite converted (EZ DNA Methylation kits, Zymo 
Research, D5003) per Illumina’s recommendation. The samples were processed and hybridized 
to Infinium MethylationEPIC BeadChip (Illumina, WG-317-1002) and signal was scanned with 
Table 5. Clinical and demographic characterization of the HBS study cohort. Values are 
expressed means with (S.D.) *** indicates p value <0.001 and ** indicates p value <0.01 for 
inter-group comparisons as per Student’s t test.  (1) Age expressed in years. (2) Education 
expressed in years. College or above =16; High school= 12; elementary school = 5. (3) 
Disease duration is calculated in years since diagnosis. A value of 0 is assigned is at baseline 
if the patient has received a diagnosis of PD during the same year of enrolling in the study. 
(4) Modified Hoehn and Yahr scale for clinical staging of Parkinson’s disease (Goetz et al. 
2004). (5) Indicates pvalue of Welch two-sided two-sample t-test comparing the indicated 
category between enrollment and follow-up visits. Female and Male groups were analyzed 
separately. Only provided for significant differences. (6) Mini-Mental State Examination. (7) 
White blood cells count. (8) Red blood cells count. (9) De novo patients that yet did not 
receive any type of anti-parkinsonian medication. (10) Based on Parkinson’s disease 
treatment that may affect one-carbon metabolism as defined in our study, including Sinemet; 
Comtan and Stalevo. Data was not available for: HY enrollment 2 cases; HY follow-up 13 PD 
cases; MMSE enrollment 61 CT cases; MMSE follow-up 67 CT and 2 PD; WBC/RBC 
enrollment 10 CT and 6 PD; WBC/RBC follow-up 48 CT and 50 PD cases. 
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Illumina’s iScan.  Longitudinal sample pairs corresponding to the same subjects were run on the 
same chip to avoid batch effects. Raw IDAT files were exported for processing in R.  
Data Normalization and Quality Control 
 The study was conducted at the laboratories of Dr. Dunckley at Arizona State University 
(ASU) and Dr. Desplats at University of California San Diego (UCSD). Both laboratories applied 
unified standard operating procedures (SOPs) according to Illumina’s recommendations. We 
performed careful quality control and pre-processing steps using the R Bioconductor package 
Minfi v. 1.22.1 (Aryee et al. 2014). Detection P values were calculated. No samples had mean 
detection P value > 0.05.  Sex prediction was performed and 8 samples with discordant calls 
were removed from the analysis. Subject identity in paired-samples was determined using SNPs-
matching probes contained in the EPIC array (Heiss and Just 2018). Samples with ratios of non-
methylated/methylated sites (uMeth/mMeth) < 10.5 were also removed. The call rate was 
calculated as the proportion of probes in each sample with a detP of < 0.01. Samples with detP > 
.99 were removed. We ran technical replicates across sites and batches for control. Replicates 
were removed by taking the sample with the highest call rate. As a result, a total of 36 samples 
were removed from downstream analyses and the remaining 792 samples (two time-point 
longitudinal samples from 197 PD cases and 199 controls) were normalized using ssNoob, a 
method recommended for EPIC array data processing (Fortin et al. 2017). After normalization, 
probes were removed that failed in one or more samples (detP > 0.01), were located on sex 
chromosomes, had SNPs at the CpG site, or documented to be cross-reactive from Pidsley et 
al.(Pidsley et al. 2016), leaving 755,625 probes for analysis. In addition, we evaluated the 
correlation of intensities between sample replicates and longitudinal pairs repeated across the 
arrays to verify association.  
Methylation Data Analysis: PD vs Control with repeated measures 
 All probes were used to build multi-dimensional scale plots to visualize the variation in the 
data. Probe-wise differential methylation analysis was performed with the Bioconductor package 
limma. Beta values were converted to M-values for statistical analysis. Consensus correlation 
was calculated for longitudinal samples using the limma duplicateCorrelation function using 
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10,000 randomly selected probes and patient ID as the block parameter. The model design for 
the longitudinal analysis was ~0+condition_visit + batch_site + age + sex + smoke + 
duration_at_baseline + CD8T+CD4T+NK+Bcell+Mono+Gran, and was adjusted as needed to test 
PD vs CT . The limma function lmFit including patient ID as the block variable and the consensus 
correlation from duplicate-Correlation() function was run with the specified design on M-values, 
followed by fitting the desired contrasts and running the limma function eBayes to calculate 
differentially methylated probes. The corresponding Beta value is also included in tables and was 
used to calculate differential methylation as Delta Beta between the indicated comparisons. 
Differentially methylated regions (DMRs) were analyzed using DMRcate(Peters et al. 2015a).  
Longitudinal analysis 
 
 Longitudinal analysis was performed on different subsets of the data (Control only, PD 
only, Medication true only and Medication false only).  On each of these datasets, we fit a linear 
model by robust regression using an M estimator with the R function rlm in the R package MASS.  
The model is outlined below and includes the covariates baseline age (blineAge), sex, cell type 
composition, site, smoking status (smoked) and duration at baseline plus time between visits 
(duration_plus_time). The term “time” in the model is composed by the sum of disease duration at 
baseline (which = 0 in control subjects or PD cases diagnosed less than one year before baseline 
sample) and the time interval between baseline and follow-up samples.   
Rlm (x~blineAge+Sex+CD8T+CD4T+NK+Bcell+Mono+Gran+Site+Smoked+duration plus time  
-1, maxit=100). 
 
RESULTS 
 
  Our study included 380 participants from the Harvard Biomarker Study, 189 patients with 
PD (31% females; average age of 68 at enrollment visit) and 191 control subjects (34% females; 
average age of 69 at baseline, Table 5). From the 380 participants, 313 self-reported as white 
non-Hispanic; 40 as white Hispanic/Latino; 1 as Asian non-Hispanic; 2 as African-American 
Hispanic/Latino. Data was not available for the remaining 24 subjects.  Levels of education did 
not significantly vary between cases and controls and overall 82% of participants attended 
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college. There were no significant differences in red or white blood cell count (as reported in 
blood tests) or in cognitive status (as per Mini-Mental State Examination, MMSE) between cases 
and controls at baseline or follow-up. We profiled samples obtained at the enrollment visit 
(baseline point) and a longitudinal sample corresponding to the second visit, which was collected 
on average 2.2 years later (S.D.=0.85) and used as the follow-up point. The time elapsed 
between visits ranged between 0.8 and 11.98 years and the mean of distributions was similar 
between controls and PD cases (p=0.2206 as per unpaired t-test). We selected PD cases with 
confirmed clinical diagnoses and with Hoehn and Yahr scale scores ≤ 3 at baseline, representing 
early or mild PD.  Disease duration was similar between female and male PD patients, with an 
average duration of 3.7 years (S.D.=3.97) at baseline. During the period elapsed between 
baseline and follow-up visits no changes in cognition were observed in controls, while PD patients 
showed decay in MMSE performance, which was only significant for males (Table 5). Smoking 
has been largely reported as a protective factor and inversely correlated with the occurrence of 
PD(Ascherio and Schwarzschild 2016) . In our study 41.8 % of PD cases and 29.8 % of controls 
reported to have previously smoked. The number of active smokers was low with only 1 PD case 
being an active smoker in comparison to 7 control subjects still smoking (Table 5). Smoking 
status did not change between baseline and follow up visits and was included as a covariate in 
our analysis. Overall, PD patients showed a worsening in clinical manifestations as per HY 
scores, which changed significantly between baseline and follow up visits (p<0.0001, as per 
paired t-test), indicating disease progression. Similarly, the Unified Parkinson's Disease Rating 
Scale (UPDRS) total scores increased between baseline and follow-up visits at an average rate 
of 3.05 points/year (p<0.0001, as per paired t-test), consistent with disease worsening.  
Estimation of blood cell composition using methylation data. 
 We used whole blood DNA to profile methylation; therefore, different lymphocyte cell type 
distributions between cases and controls may confound the analysis. We used distinctive cell-
specific methylation profiles to estimate the proportional abundance of blood cell types and to 
evaluate whether alterations in white blood cell composition may be associated with PD 
pathology and have the potential to drive differential methylation between cases and controls. We 
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applied the “estimate-CellCounts” function in minfi (Jaffe and Irizarry 2014) to estimate the 
proportional abundance of blood cell types in our study samples by integrating the intensity of 
specific probes present in the EPIC array. We observed that granulocytes (as a group, including 
neutrophils) were the most abundant cells in blood, as expected (Fig. 4). Overall blood cell 
composition varied between control and PD groups. At baseline, PD patients showed higher 
estimated levels of granulocytes (p=4.0E-6, as per t-test) and lower estimated B-cells (p=0.0019) 
and NKs (p=0.00055) in comparison to controls. These differences only persisted for 
granulocytes, which were higher in PD cases (p=0.0066) and natural killers, which were lower in 
PD (p=0.00065) in the follow-up visit. Intra-group analysis showed that only granulocytes 
(p=0.00063) changed longitudinally in control subjects, while no changes were observed in PD 
cases between the time points analyzed (Fig. 4). 
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Figure 4. Comparison of individual cell type across control (CT) and PD groups at enrollment 
(e) and follow-up (f). Abundance of specific blood cell types was estimated based on unique 
methylation markers for cell identity. Shown in (A) granulocytes, in (B) B cells, in (C) natural 
killer cells, in (D) CD4T cells, in (E) CD8T cells, and in (F) monocytes. Blue solid line indicates 
comparison between PD cases vs. CT subjects at enrollment; black solid line indicates 
comparison between PD cases vs. CT subjects at follow-up; dash blue line indicates 
comparison between PD cases at follow-up vs. enrollment time points; dash black line 
indicates comparison between CT subjects at follow-up vs. enrollment time points. P-value for 
the differences in cell composition estimates across groups as per Wilcoxon test after 
correction for multiple observations are indicated. 
Figure 1 Click here to access/download;Figure;Rev.Figure 1.tiff
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Methylation changes associated with Parkinson’s disease: cross-sectional analysis.  
 We first conducted a cross-sectional analysis by comparing methylation profiles between 
cases and controls regardless of time of visit to define disease-associated changes in 
methylation, while accounting for repeated measures, using limma. We identified 7 probes 
showing differential methylation (DMPs) in PD with genome-wide scale significance at a p-value < 
5.0E-7 (adjusted pvalue<0.05) and another 46 DMPs with marginal significance of adj. p < 0.2 
(Fig. 5; Table 6). Overall changes in methylation were modest, with |log2 FC| <0.6 (in M-values). 
Among the top changes in this group, we identified multiple CpGs clustering around 200 bp of the 
TSS of the Lamin Tail Domain Containing 1 (IFLTD1/LMNTD1), an intermediate filament protein, 
and Delta Like Non-Canonical Notch Ligand 1 (DLK1), a transmembrane protein involved in 
differentiation of multiple cell types. Additional functional categories represented in this list (Table 
6) include microtubule associated proteins Doublecortin Like Kinase 1 (DCLK1: p=3.19E-6) and 
Dynein Cytoplasmic 1 Heavy Chain 1 (DYNC1H1: p=3.24E-6); the transcription factor LIM 
Domain Only 3 (LMO3: p= 3.68E-6), and a neurotransmission regulator synaptotagmin 12 
(SYT12: p=2.79E-7). These represent diverse cellular processes, some of which would not be 
expected to be important in blood cells (LMO3, which is highly expressed in brain(Sang et al. 
2014); SYT12, essential in synaptic transmission(Kaeser-Woo et al. 2013)). Thus, these findings 
may be reflective of similar alterations in the brain. This is supported by the finding of CYP2E1 in 
this study (Table 6) and previous reports of altered CYP2E1 methylation in the PD brain(Kaut et 
al. 2012). 
 Noteworthy, many DMPs associated with PD present intermediate levels of methylation 
(ecific s>0.2 and <0.8), which represent the more dynamic portion of the methylome and more 
likely to respond to environmental/physiological cues, and which may reflect intrinsic alterations 
due to disease progression.   
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Name Chr Position Relation to TSS Gene ID 
Fold 
Change 
(log2) 
P-Value FDR 
cg06889422 22 24627294 Body N/A -0.284 1.28 x 10-8 0.0039 
cg16133681 12 25801621 TSS200 IFLTD1 -0.386 1.54 x 10-8 0.0039 
cg26524067 12 133003928 Open Sea N/A -0.497 1.55 x 10-8 0.0039 
cg09994891 10 2173024 Open Sea N/A 0.319 1.31 x 10-7 0.0248 
cg11408952 13 48892244 Body RB1 0.486 1.72 x 10-7 0.0260 
cg12724357 11 66790285 TSS1500 SYT12 0.241 2.79 x 10-7 0.0351 
cg08098382 19 3869345 TSS1500 ZFR2 0.307 4.35 x 10-7 0.0470 
cg23979954 12 25801601 TSS200 IFLTD1 -0.306 6.65 x 10-7 0.0623 
cg18279536 14 101194748 Body DLK1 0.183 8.04 x 10-7 0.0623 
cg10405605 10 6188149 TSS200 PFKFB3 0.152 8.24 x 10-7 0.0623 
cg04741728 12 133003907 Open Sea N/A -0.594 1.17 x 10-6 0.0768 
cg20787649 1 17636898 Body N/A 0.530 1.22 x 10-6 0.0768 
cg03681383 12 25801522 TSS200 IFLTD1 -0.304 1.56 x 10-6 0.0907 
cg12342048 19 11465311 Body AC024575.1 -0.247 2.16 x 10
-6 0.1081 
cg19628497 14 101194267 Body DLK1 0.205 2.22 x 10-6 0.1081 
cg13211181 12 25801455 1stExon IFLTD1 -0.268 2.52 x 10-6 0.1081 
cg00515755 19 1005248 Body N/A 0.204 2.57 x 10-6 0.1081 
cg11469325 10 75012359 1stExon MRPS16 -0.299 2.57 x 10-6 0.1081 
cg04224786 8 144222401 Open Sea N/A 0.270 3.03 x 10-6 0.1096 
cg08766508 13 36430582 TSS1500 DCLK1 0.315 3.19 x 10-6 0.1096 
cg25588820 12 108070383 Open Sea N/A -0.278 3.19 x 10-6 0.1096 
cg12127149 14 102487020 Body DYNC1H1 0.094 3.24 x 10-6 0.1096 
cg05763097 14 103569340 Body EXOC3L4 0.297 3.33 x 10-6 0.1096 
cg01181415 12 16757954 5'UTR LMO3 -0.140 3.68 x 10-6 0.1126 
cg18121862 14 101195312 Body N/A 0.153 3.72 x 10-6 0.1126 
cg13315147 10 135341528 Body CYP2E1 0.356 4.02 x 10-6 0.1170 
cg18397450 14 105830631 Body PACS2 -0.380 4.56 x 10-6 0.1220 
cg21435367 3 133574742 Body RAB6B -0.252 4.80 x 10-6 0.1220 
cg15756507 17 65471461 Body N/A 0.139 5.05 x 10-6 0.1220 
 
Figure 5. Case versus control comparisons in the HBS study. Representative box plots of top 
significant DMPs showing decreased (A) or increased (B) methylation in PD cases in 
comparison to control subjects. (C)  Manhattan plot compiling genome-wide methylation sites 
and highlighting significant DMPs for the cross-sectional comparison PD vs. CT. Red line 
indicates significance cut-off at FDR<0.05. 
Table 6. Top differentially methylated probes (DMPs) in PD in the cross-sectional analysis. 
Name indicates probe designation at Illumina EPIC human methylation array; chr is 
chromosome location of the CG; position refers to Genome Reference Consortium Human 
Build 37 (GRCh37) hg19; N/A indicates no annotated gene associated with the probe.  
  
  35 
 
Identification of Differentially Methylated Regions. 
 DNA methylation is influenced by CpG topology and methylation in one site is dependent 
on the methylation status of nearby CpGs by potential cooperation in recruiting 
methylating/demethylating factors, extending their activity in wider local DNA domains (Lovkvist et 
al. 2016). CpG clusters showing concerted changes in methylation are deemed highly relevant in 
the modulation of transcription. We searched for differentially methylated regions (DMRs), or 
groups of at least 4 CpGs within proximal genomic locations using DMRCate(Peters et al. 2015a), 
a stringent model that links proximal sites after testing their significance as individual DMPs (Fig. 
6, Table 7). Among the top DMRs in PD, we identified CYP2E1, with 13 CGs altered (p=1.22E-
22). This gene was one of the first reported as differentially methylated in PD brains (Kaut et al. 
2012). Therefore, our results in whole blood are consistent with this previous finding and support 
a role for methylation in regulating this gene, which contributes to cholesterol and lipid 
metabolism, pathways that are altered in PD, also highlighting the utility of whole blood profiling. 
Another notable DMR is LY6G5C, with 5 CGs altered (p=3.92E-9), which has recently been 
identified in brain tissue as an epigenetic marker of schizophrenia (Wockner et al. 2015). 
 
 
 
 
 
 
 
 
 
 
 
 
  36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Graphical representation of differentially methylated regions (DMRs) in PD cases 
in the cross-sectional study. Representative schematics for top DMRs (Table 3) associated 
with CYP2E1 (A); LY6G5C (B) and CCDC89 (C). Genomic location is indicated by 
chromosome position (based on Genome Reference Consortium Human Build 37 (GRCh37) 
hg19). Transcripts are indicated by light blue arrows. CGs appear as green lines. Red line 
represents Delta Beta of PD vs CT comparison for all the CGs constituting the significant 
region. 
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Chr start end probes in region minFDR Stouffer 
max beta 
fold 
change 
overlapping 
promoters 
Regions with increased methylation in PD cases 
10 135341025 135343248 13 1.22 x 10-22 0.00004 0.06768 CYP2E1 
19 54945959 54946993 6 4.14 x 10-15 0.00019 0.05752 AC008746.3 
18 72916776 72917390 6 1.14 x 10-10 0.03901 0.04425 ZADH2 
8 144222015 144222455 5 2.54 x 10-18 0.00001 0.04395 NA 
1 153599479 153600156 15 1.05 x 10-12 0.10454 0.04178 S100A1 
11 2889840 2891360 35 1.04 x 10-20 0.81658 0.03802 KCNQ1DN 
14 101194145 101195312 4 9.83 x 10-17 0.00000 0.03520 DLK1 
6 31650786 31650930 5 3.92 x 10-9 0.38577 0.03252 LY6G5C 
6 28983835 28984341 5 6.2 x 10-12 0.19530 0.03166 NA 
17 65471303 65471507 5 2.45 x 10-9 0.02194 0.02850 NA 
6 29599012 29599390 9 1.19 x 10-11 0.23989 0.02814 GABBR1 
10 6187854 6188415 5 2.87 x 10-14 0.00086 0.02319 PFKFB3 
15 91473059 91473569 10 2.38 x 10-11 0.02671 0.02146 UNC45A 
6 32144667 32146779 35 8.45 x 10-25 0.05366 0.01962 AGPAT1 
16 3114847 3115809 12 7.41 x 10-17 0.00671 0.01755 IL32 
Regions with decreased methylation in PD cases 
6 28945189 28945507 7 2.77 x 10-13 0.00338 -0.04644 RN7SL471P 
8 57350735 57351067 5 1.06 x 10-10 0.06139 -0.04393 PENK 
6 164506692 164507305 9 3.77 x 10-12 0.03187 -0.04304 RP1 
12 25801455 25801945 6 9.6 x 10-29 0.00000 -0.04099 IFLTD1 
13 111521981 111522651 5 2.12 x 10-12 0.00725 -0.04075 LINC00346 
10 77542302 77542585 9 1.28 x 10-12 0.01495 -0.03571 LRMNDA 
2 48844369 48845068 10 8.32 x 10-17 0.04500 -0.03301 GTF2A1L 
6 31409319 31409757 12 1.48 x 10-10 0.22543 -0.02132 LINC01149 
5 138210632 138211184 12 4.46 x 10-12 0.05387 -0.01719 LRRTM2 
 
Methylation changes associated with PD progression: longitudinal analysis.  
 The main goal of our study was to investigate whether blood DNA methylation changes 
as PD pathology progresses. We fit linear models by robust regression using an M estimator 
using the rlm() function in the R MASS package to identify genomic sites where methylation 
Table 7. Differentially methylated regions (DMRs) associated with PD. Start and end indicate 
with the genomic coordinates for location of the defined DMR based on Genome Reference 
Consortium Human Build 37 (GRCh37) hg19. # CG indicates how many CGs were included in 
the DMR; minFDR is the minimum adjusted p-value from the CGs constituting the significant 
region; Stouffer is the Stouffer transformation of the group of FDRs for individual CGs at the 
DMR; max beta fold change is the maximum absolute fold change within the region. 
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varies over time in PD cases. We identified 138 DMPs that significantly changed over time in PD 
cases only at p<1.0E-7 with a rate of change ranging from a 0.8 % increase and a 0.6% decrease 
in methylation per year and supporting dynamic methylation changes in the blood methylome 
associated with disease progression (Table 8). Aging is an important determinant of DNA 
methylation (Fraga and Esteller 2007; Horvath et al. 2012). Although we controlled for age in our 
models; we also calculated the association of methylation changes with age to rule out that aging 
was the main driver of the longitudinal epigenetic changes we observed in PD. We observed a 
significant association with age for only 2/138 probes changing in PD over time. Furthermore, 
none of these longitudinal DMPs overlap with probes composing the epigenetic clock from 
Horvath (Horvath 2013), further supporting that the observed changes are due to disease 
progression. We used Ingenuity Pathway analysis to interrogate pathway enrichment in the 
differentially methylated probes. For this analysis we applied a less stringent cut-off criteria at 
p<1.0E-6 (886 DMPs and 534 mapped genes entered into the analysis). Notably, the top 
category enriched in the Disease and Function annotation was neurological disorders; including 
13 genes associated with Alzheimer’s disease (p=1.08E-2). Among enriched canonical pathways, 
biotin-carboxyl carrier protein showed a significant p-value of 2.25E-3, including DMPs mapping 
to Acetyl-CoA carboxylase alpha (ACACA), the rate limiting enzyme in the synthesis of long chain 
fatty acids. Interestingly, decreased long-chain acylcarnitines have been recently proposed as 
potential early diagnostic markers for PD (Saiki et al. 2017).  
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Probe ID Chr Position Gene ID 
Change 
rate  
PD 
Pvalue 
PD 
Change 
rate 
Controls 
Pvalue 
Controls 
Methylation decreasing over time 
cg26275301 17 81041828 METRNL -0.604 7.56 x 10-8 -0.00026 6.93 x 10-1 
cg07856430 18 42339206  -0.525 8.67 x 10
-9 -0.00058 2.85 x 10-1 
cg13153353 7 4175865 SDK1 -0.524 5.43 x 10-8 0.00244 2.30 x 10-5 
cg03565777 12 125028339 NCOR2 -0.508 8.40 x 10-8 -0.00276 1.38 x 10-6 
cg24136431 19 47016623  -0.392 6.40 x 10
-8 -0.00045 2.93 x 10-1 
cg16655626 19 45886078  -0.334 2.46 x 10
-9 0.00152 4.38 x 10-1 
cg04843111 1 156617074 BCAN -0.328 1.00 x 10-9 -0.00088 6.64 x 10-1 
cg08988821 7 74075293 GTF2I -0.326 4.22 x 10-8 -0.00107 6.71 x 10-1 
cg01791421 1 19996240  -0.309 8.38 x 10
-8 -0.00105 2.19 x 10-3 
cg13994376 13 112554122 LINC00354 -0.292 1.25 x 10-8 0.00005 8.71 x 10-1 
cg15987655 5 139196457  -0.278 5.86 x 10
-8 -0.00285 1.42 x 10-1 
cg03389720 16 8780048 ABAT -0.277 2.00 x 10-8 -0.00091 1.88 x 10-3 
cg15765398 21 46409994 LINC00163 -0.272 5.57 x 10-9 -0.00114 4.16 x 10-1 
cg09750643 11 1718086 KRTAP5 -0.257 8.04 x 10-9 -0.00022 4.07 x 10-1 
Methylation increasing over time 
cg17046825 13 21081216  0.834 5.35 x 10
-8 -0.00311 6.60 x 10-4 
cg26126295 4 119095240  0.775 1.78 x 10
-8 0.00030 9.44 x 10-1 
cg06688960 20 1504932  0.713 1.04 x 10
-9 -0.00053 8.49 x 10-1 
cg25979148 4 871629  0.210 2.55 x 10
-8 -0.00001 9.95 x 10-1 
cg15540764 7 36919658 ELMO1 0.140 7.33 x 10-8 -0.00040 9.61 x 10-3 
cg05933219 2 240099221 HDAC4 0.134 5.61 x 10-8 -0.00058 4.87 x 10-1 
cg14946911 20 56772325  0.128 2.24 x 10
-9 0.00001 9.90 x 10-1 
cg09593391 8 144737908 ZNF623 0.126 9.53 x 10-8 -0.00017 8.51 x 10-1 
cg18496624 17 38094692  0.123 5.44 x 10
-9 -0.00005 7.14 x 10-1 
cg10401356 8 140712424  0.123 1.11 x 10
-8 0.00037 6.62 x 10-1 
cg08561469 16 81944150 PLCG2 0.116 3.38 x 10-9 0.00002 8.52 x 10-1 
cg15475168 7 101860421  0.115 1.16 x 10
-8 -0.00023 7.69 x 10-1 
cg20397902 16 88624807  0.109 1.06 x 10
-8 -0.00023 7.43 x 10-1 
cg01202950 15 74943647 EDC3 0.106 6.20 x 10-9 -0.00027 6.90 x 10-1 
 
 
 
Table 8. Top longitudinal changes in methylation in PD cases. Name indicates probe 
designation at Illumina EPIC human methylation array; chr is chromosome location of the CG; 
position refers to Genome Reference Consortium Human Build 37 (GRCh37) hg19; N/A 
indicates no annotated gene associated with the probe. Rate of change indicates percentage 
methylation change/year.  
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Longitudinal methylation changes associated with PD medication. 
 Dopamine replacement is the standard of clinical care for Parkinson’s disease and the 
vast majority of patients receive dopamine precursors, like levodopa/carbidopa (commercialized 
as Sinemet or Stalevo) and/or inhibitors of Catechol-O-methyltransferase (COMT; commercial 
name Comtan). Importantly, the metabolism of these compounds directly impact the one-carbon 
pathway, potentially affecting the supply of methyl-group donor molecules and the activity of DNA 
methyltransferases (Fig.7).  Although current levopoda products are formulated to prevent break-
down in the gastrointestinal tract and systemic circulation, the potential impact of these drugs on 
blood methylation has not been explored at genome-wide scale before. Therefore, we analyzed 
the effect of anti-parkinsonian therapy on DNA methylation by defining the category “PD 
Medication”. PD cases receiving Sinemet; Stalevo and/or Comtan, either as single drugs or in 
combination at any dose and at any time point were categorized as the PD medication group. PD 
cases that did not take any of these drugs by the time of blood sampling were coded as PD NOT 
medicated. According to this classification, 69 patients were grouped as “PD NOT Medicated”, 
from which 27 remained unexposed to these drugs at the follow-up visit.  
We first analyzed longitudinal changes in methylation in the group of PD cases receiving PD 
medication. We identified 237 probes showing significant changes of methylation over time at a 
p<1.0E-7 and showing modest changes in methylation ranging in the order of 0.63 % reduction 
and 0.86 % increase in methylation/year (Table 9; Fig. 8). Longitudinal methylation in these sites 
did not change significantly in control subjects. Only 23/237 of the probes changing in the PD 
medicated group were significantly associated with aging, The remaining 214 CpG sites showed 
longitudinal changes in patients taking medication, which are likely involved in both the effect of 
medication and PD progression over time. Genes tagged by these CpGs (Table 9) function as 
transcription factors (ZNF544, ZNF623, GTF2I), extracellular matrix proteins (BCAN), non-coding 
RNAs (Y_RNA, LINC00163), neural cell adhesion (PCDH1), and synaptic transmission 
(RIMBP2), once again suggesting that signals related to central nervous system dysfunction can 
be detected in peripheral blood DNA.  
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Probe ID Chr Position Gene ID 
Change 
rate  
PD Med 
Pvalue  
PD Med 
Change 
rate 
Controls 
Pvalue 
Control 
Methylation decreasing over time 
cg13643943 5 138629019 MATR3 -0.0632 7.25 x 10-8 -0.00417 2.26 x 10-1 
cg08988821 7 74075293 GTF2I -0.0396 7.24 x 10-9 -0.00107 6.71 x 10-1 
cg16655626 19 45886078  -0.0373 2.20 x 10
-8 0.00152 4.38 x 10-1 
cg14386312 19 58740861 ZNF544 -0.0346 2.92 x 10-8 -0.00204 2.90 x 10-1 
cg15765398 21 46409994 LINC00163 -0.0344 1.11 x 10-11 -0.00114 4.16 x 10-1 
cg15987655 5 139196457  -0.0329 1.98 x 10
-8 -0.00285 1.42 x 10-1 
cg04843111 1 156617074 BCAN -0.0327 8.26 x 10-8 -0.00088 6.64 x 10-1 
cg14240188 1 11621054  -0.0281 1.77 x 10
-8 0.00038 8.03 x 10-1 
cg04551581 18 44226771  -0.0273 5.48 x 10
-8 -0.00150 3.08 x 10-1 
cg15298173 15 29903900 RP11-300A12 -0.0262 7.18 x 10-8 -0.00297 5.48 x 10-2 
cg15202607 5 149520120 PDGFRB -0.0234 4.44 x 10-8 -0.00151 1.89 x 10-1 
cg10429957 5 141245719 PCDH1 -0.0197 8.39 x 10-8 -0.00139 2.38 x 10-1 
Methylation increasing over time 
cg26126295 4 119095240  0.0862 8.67 x 10
-8 0.00030 9.44 x 10-1 
cg25979148 4 871629  0.0252 4.47 x 10
-9 -0.00001 9.95 x 10-1 
cg10224806 12 131188144 RIMBP2 0.0221 9.04 x 10-8 0.00156 1.16 x 10-1 
cg18629514 7 5388895  0.0178 8.06 x 10
-8 0.00025 7.94 x 10-1 
cg03501539 11 114760598  0.0166 6.57 x 10
-8 0.00014 8.87 x 10-1 
cg15008072 17 7440546 Y_RNA 0.0166 7.51 x 10-8 0.00113 2.20 x 10-1 
cg05933219 2 240099221 HDAC4 0.0162 1.37 x 10-9 -0.00058 4.87 x 10-1 
cg18763089 1 1683738 NADK 0.0155 1.10 x 10-8 0.00067 3.78 x 10-1 
cg05120150 14 105912598 MTA1 0.0143 3.80 x 10-8 0.00006 9.39 x 10-1 
cg09593391 8 144737908 ZNF623 0.0139 8.19 x 10-8 -0.00017 8.51 x 10-1 
cg10401356 8 140712424  0.0138 3.24 x 10
-9 0.00037 6.62 x 10-1 
cg22511774 13 114746915   0.0137 3.27 x 10-8 0.00036 6.52 x 10-1 
 
Figure 7. Cross-talk between one-carbon metabolism and Levodopa catabolism. Diagram 
depicting the effects of dopamine metabolism on the one-carbon metabolic pathway. 
Conversion of levodopa to dopamine requires the breakage of S-adenosyl methionine as 
methyl group donor which is the same source of methyl groups used by DNA methyl 
transferases (DNMTs) to methylation cytosine residues. In addition, homocysteine produced 
by the conversion levodopa-dopamine is an inhibitor of DNMTs activity and may alter DNA 
methylation. COMT further mediates the conversion of dopamine into O-methyl derivatives (3-
methoxytyramine) by consuming methyl groups from SAM. The potential interaction with PD 
medication are indicated, with Sinemet and Stalevo increasing levodopa levels and COMTAN 
inhibiting COMT activity. 
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Longitudinal methylation changes in the absence of medication associated solely with PD 
progression.  
 One of the most valuable analyses in our study is the possibility of exploring the blood 
methylome in PD patients that did not yet receive PD medication. Despite the limitation of a 
reduced cohort size (N=27), this comparison may unveil epigenomic alterations only due to PD 
systemic pathophysiology. We thus analyzed changes in methylation over time in PD NOT 
medicated cases (according to the criteria for PD medication described in the previous section). 
We identified 24 probes showing significant changes of methylation over time at a p<1.0E-7. 
Notably these sites showed the largest size effects compared to the other analysis groups, with 
methylation changes ranging from a 1.5 % reduction to a 1.7 % increase in methylation/year 
(Table 10 and Fig. 8). Longitudinal methylation in these sites did not change significantly in 
control subjects and none of the sites showed association with age. Genes showing differential 
methylation in this group (Table 10) include those involved in cytoskeletal functioning, like 
microtubules (KIF19, KIF22, TAOK2, MAPK13, CEP70) and actin (SWAP70). In addition, genes 
involved in immune response are also noted (RAIT1E and TRBV4). Interestingly, changes 
observed in this group are distinct from those identified in the PD medicated group above (Table 
9). This supports the conclusion that dopamine replacement therapy indeed alters the methylome 
of PD patients (see Discussion). 
 
 
Table 9. Top Longitudinal changes in methylation in PD cases receiving medication. Name 
indicates probe designation at Illumina EPIC human methylation array; Chr is chromosome 
location of the CG; position refers to Genome Reference Consortium Human Build 37 
(GRCh37) hg19. Rate of change indicates percentage methylation change/year.  
Figure 8. Longitudinal changes in the blood methylome associated with PD progression are 
compensated by PD medication. Representative plots showing regression of methylation 
(individual β-values) as a function of disease duration and time between baseline and follow-
up samples. Comparison of top changing probes between controls (A); PD cases NOT 
receiving medication (B) and PD cases on medication. Coefficient of change as determined by 
mixed linear models (Tables 5 and 6) and corresponding p-values are indicated.  
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Probe ID Chr Position Gene ID 
Change 
rate PD 
No Med 
Pvalue PD 
Med 
Change 
rate 
Controls 
Pvalue 
Control 
Methylation decreasing over time 
cg14952312 17 72350710 KIF19 -1.537 2.41 x 10-9 -0.00156 6.41 x 10-1 
cg18812198 11 68715658  -1.324 7.66 x 10
-8 0.00114 6.95 x 10-1 
cg15969149 10 77352287  -1.054 1.61 x 10
-8 0.00087 7.34 x 10-1 
cg15531997 10 34999169  -0.981 5.39 x 10
-12 0.00023 8.71 x 10-1 
cg19174044 20 18446362 DZANK1 -0.914 3.71 x 10-8 0.00091 6.32 x 10-1 
cg13937758 6 150217448 RAET1E -0.711 3.55 x 10-8 -0.00227 1.83 x 10-1 
Methylation increasing over time 
cg14771419 7 142012988 TRBV4 1.713 1.03 x 10-9 -0.00114 7.31 x 10-1 
cg16134323 5 140562034 PCDHB16 1.507 7.50 x 10-10 -0.00042 8.29 x 10-1 
cg13252209 16 51603716  1.279 1.78 x 10
-8 -0.00192 5.70 x 10-1 
cg03700944 6 46703468 PLA2G7 1.093 8.90 x 10-9 -0.00262 2.94 x 10-1 
cg06688960 20 1504932  0.988 3.41 x 10
-8 -0.00053 8.49 x 10-1 
cg26421310 1 25257058 RUNX3 0.093 2.43 x 10-8 -0.00055 3.31 x 10-3 
cg27380788 16 4526765 NMRAL1 0.073 9.24 x 10-8 -0.00046 2.78 x 10-3 
cg11107196 16 71918265 ZNF821 0.065 5.36 x 10-9 -0.00019 1.37 x 10-1 
cg09585751 6 24646282 KIAA0319 0.056 9.21 x 10-8 -0.00021 4.51 x 10-2 
cg14934866 16 29985156 TAOK2 0.053 7.30 x 10-8 -0.00023 7.87 x 10-2 
cg21645604 6 36098567 MAPK13 0.043 3.31 x 10-8 -0.00014 5.70 x 10-2 
cg07038191 16 29801882 KIF22 0.041 5.83 x 10-8 -0.00028 3.27 x 10-4 
cg23993697 11 9685562 SWAP70 0.040 7.05 x 10-8 -0.00012 2.22 x 10-1 
cg17129217 9 91933717 SECISBP2 0.039 6.52 x 10-8 -0.00022 5.45 x 10-3 
cg15193793 14 90422250 EFCAB11 0.038 8.37 x 10-8 -0.00012 2.83 x 10-1 
cg19116545 3 138313166 CEP70 0.037 3.02 x 10-8 -0.00022 8.33 x 10-3 
cg18104674 18 60190218 ZCCHC2 0.036 5.58 x 10-8 -0.00011 9.65 x 10-2 
cg20390702 12 8850385 RIMKLB 0.036 6.54 x 10-8 -0.00019 1.85 x 10-2 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10. Longitudinal changes in methylation in PD cases NOT receiving medication. Name 
indicates probe designation at Illumina EPIC human methylation array; chr is chromosome 
location of the CG; position refers to Genome Reference Consortium Human Build 37 
(GRCh37) hg19; N/A indicates no annotated gene associated with the probe. Rate of change 
indicates percentage methylation change/year.  
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DISCUSSION 
 
Specific blood cell types are altered in Parkinson’s disease. 
 Blood methylation profiles have been used to estimate the relative abundances of 
specific blood cell types in Parkinson’s disease(Horvath 2013). In the HBS cohort, we observed 
similar significant increases in granulocytes of PD patients (p=4.0E-6, as per t-test) and lower 
estimated B-cells (p=0.0019) and NKs (p=0.00055) in comparison to controls. These differences 
remained in the longitudinal samples (~ 2 years later) for granulocytes, which were higher in PD 
cases (p=0.0066) and natural killers, which were lower in PD (p=0.00065) in the follow-up visit. 
The finding of increased granulocytes in PD confirms prior reports. However, in contrast to these 
reports, we also observe significant and persistent reductions to NK cells in PD, whereas no 
changes were previously observed for this blood cell type. While the mechanistic explanations for 
these changes will require additional study, it is tempting to speculate that changes in these 
immune related cells could reflect ongoing inflammatory responses that occur in the brain during 
PD. 
Specific whole blood methylation changes correlate with Parkinson’s disease. 
 Epigenetic changes are emerging as contributing factors to PD and other 
neurodegenerative diseases. To identify a comprehensive set of differentially methylated sites 
associated with PD, we performed a case versus control comparison on extremely well 
characterized and phenotyped patient samples acquired by the Harvard Biomarkers Study (HBS). 
Leveraging the full cohort size of 792 samples, a comparison of PD versus control groups 
identified 7 DMPs significantly associated with PD, many of them tagging genetic loci with 
interesting functional consequences with respect to pathways and cellular functions previously 
implicated in PD.  
 Analysis of neighbor sites with consistent alterations in methylation or differentially 
methylated regions (DMRs), more likely to affect gene expression, identified altered methylation 
in 13 CpG sites (p=1.22E-22) at the cytochrome P450 2E1 (CYP2E1) locus in whole blood of PD 
patients. Interestingly, CYP2E1, which has been reported to be hypomethylated in PD brain 
samples (Kaut et al. 2012), encodes a member of the cytochrome P450 mixed-function oxidase 
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system responsible for metabolizing environmental toxins. Since environmental factors and 
external toxins contribute to PD vulnerability(Helley et al. 2017),  altered regulation of CYP2E1 
may signal the response to environmental cues that associate or contribute to PD onset. We 
note, however, that previous reports describe hypomethylation of the CYP2E1 locus in PD brain. 
Here we find consistent increased methylation in several CpG sites across the 5’ region of the 
gene in blood (Fig. 6A and Table 7). Reasons for this tissue specific difference remain to be 
clarified, but identification of this locus across independent studies and separate tissues suggests 
an important role in PD. Another notable DMR includes 1-acylglycerol-3-phosphate O-
acyltransferase 1 (AGPAT1: 35 CGs hypermethylated; p=8.45E-25). AGPAT1 catalyzes the 
conversion of lysophosphatidic acid (LPA) into phosphatidic acid (PA). LPA is required for 
dopamine neuron development and, in the 6-OHDA model of PD, reduced LPA has implicated in 
dopamine neuron degeneration through activity at the LPA1 receptor(Yang et al. 2015).  In 
addition, among the DMRs identified was one in the lymphocyte antigen 6 family member G5C 
(LY6G5C: 5 CGs hypermethylated; p=3.92E-9), recently identified as an epigenetic marker of 
schizophrenia(Wockner et al. 2015); and clustering in the major histocompatibility complex (MHC) 
class III region of chromosome 6, encoding genes with critical functions in immunity. Genetic 
variation of MHC associates with sporadic PD (Hamza et al. 2010), suggesting that altered 
immunity in PD may be trackable via epigenetic changes in blood. 
Longitudinal analyses reveal methylome changes over time in PD patients. 
 Analysis of samples from patients at baseline and follow-up, which averaged 2.2 years 
later, provided the opportunity to interrogate the extent to which methylation profiles of PD 
patients change over time. During the sampling interval, PD cases showed modest but highly 
significant disease progression as assessed by both HY (p<0.0001, as per paired t-test) and 
UPDRS scores (p<0.0001; see also Table 5).  
Single locus hits showing longitudinal methylation changes in PD with the highest 
statistical significance (Table 8) highlight pathways of potential importance to nervous system 
function. These include 4-aminobutyrate aminotransferase (ABAT: p=2.0E-8), which is 
responsible for breaking down the neurotransmitter γ-aminobutyric acid (GABA, and Enhancer Of 
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mRNA Decapping 3 (EDC3: p=6.2E-9); EDC3 promotes removal of the 5’ cap structure of 
mRNAs during their degradation. Recessive mutations in EDC3 cause intellectual 
disability(Ahmed et al. 2015), suggesting an impairment of neurological functions linking mRNA 
decapping to normal cognition. In addition, multiple cytoskeletal and extracellular matrix 
associated proteins showed differential methylation over time in PD, including Keratin Associated 
Protein 5-5 (KRTAP5: p=8.04E-9); Engulfment And Cell Motility 1 (ELMO1: p=7.33E-8); Brevican 
(BCAN: p=1.0E-9);  and Sidekick Cell Adhesion Molecule 1 (SDK1: p=5.43E-8). Lastly, Nuclear 
Receptor Corepressor 2 (NCOR2: p=8.4E-8) and Histone Deacetylase 4 (HDAC4: p=5.61E-8) 
were hypo- and hyper-methylated, respectively, in PD patients at the follow-up visit relative to 
baseline, suggesting potential alterations to the epigenetic machinery itself. This could be due 
either to PD progression or, potentially, to the administration of PD medications that alter one-
carbon metabolism pathways (see below). 
Dopamine replacement therapies alter the methylome in PD patients. 
 Dopamine replacement therapies directly impact one carbon metabolism, consuming 
methyl groups that are required for DNA methylation and increasing homocysteine levels, which 
directly inhibits the activity of DNA-methyl transferases (Figure 7). Determining the extent to 
which common PD medications impact methylation profiles is, therefore, critical for studying 
differential methylation in the context of PD. The HBS contains a number of PD patients that were 
not taking any medication associated with PD treatment at time of enrollment. Samples from 25 of 
these patients were included in our study. In addition, we were particularly interested in exploring 
a potential interaction between levodopa and COMT-inhibitors on DNA methylation profiles, 
therefore we grouped all PD cases that ever received Sinemet, Stalevo and Comtan as “PD 
Medication”.   
 Sinemet contains two active ingredients: levodopa and carbidopa. Levodopa is a 
dopamine agonist. Carbidopa is a peripheral inhibitor of DOPA-decarboxylase, preventing 
conversion of Levodopa to dopamine outside the brain. Stalevo is a combination of carbidopa, 
levodopa, and entacapone- an inhibitor of catechol-O-methyltransferase (COMT). Comtan is the 
commercial denomination for entacapone.  
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 The conversion of levodopa to dopamine consumes methyl-groups from the donor (SAM) 
used by DNMTs to methylate DNA. COMT further metabolizes dopamine into 3-methoxytyramine 
at expense of SAM. Therefore the 3 drugs may alter the availability of SAM and the levels of 
homocysteine, which in turn inhibits DNMTs.  
 The majority of patients were taking Sinemet during the study (n=104 at baseline and 
n=140 at follow-up); from which 13 cases at baseline and 15 at follow-up were also on Comtan. 
Comtan was never administered alone or in combination with Stalevo. Use of Stalevo was 
reported for 21 cases at baseline and 26 at follow-up. The cases using Sinemet + Comtan may 
have equivalent effects to those on Stalevo. All patients taking any combination or formulation of 
these drugs are receiving levodopa/carbidopa.  
 While we recognize that the 25 non-medicated PD cases is a relatively small sample 
size, preliminary analysis of longitudinal changes in methylation in patients naïve to these drugs 
identified 217 DMPs. These DMPs may denote true PD associations separate from any 
modifications that may be imposed by dopamine replacement medications. To the best of our 
knowledge, this is also the first genome-wide analysis of blood methylation in medication naïve 
PD cases. Importantly, the comparison between medicated versus not medicated patients 
showed larger changes in methylation longitudinally, suggesting that medication modifies the 
epigenome. Therefore, as the methylome of naïve cases better resembles the epigenetic profiles 
of the disease, they provide additional value for early diagnosis. Study of prodromal cases before 
phenoconversion and of a properly powered naïve cohort will be fundamental for the appraisal of 
methylation as an early PD classifier tool. 
 One important observation from the longitudinal analysis is the overall damping effect 
that PD medication has on the blood methylome, illustrated in the group comparison of top DMPs 
changing longitudinally in Figure 8. On one hand, as our cohort is dominated by PD cases 
receiving medication, the changes in methylation are smaller when using the entire cohort for the 
analysis. On the other hand, the larger changes in methylation in PD NOT medicated cases 
supports the utility of blood methylation as an early disease classifier and a potential indicator of 
disease progression and, eventually, drug efficacy/history. Additional studies including more 
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subjects are needed to corroborate these findings, despite the scarcity of samples from non-
medicated/naïve patients.   
 One of the limitations of our analysis is the number of time points investigated. Not only 
having only two data sets per subject restricts the analysis, but also the average longitudinal time 
lapse of ∼2 years may not be sufficient to detect significant changes in methylation beyond the 
high variability of the population. UPDRS total scores are estimated to increase by 4.7 points per 
year in PD patients not taking medication (Holden et al. 2018). In contrast, we observed only 3.05 
points/year increase in UPRDS in cases, suggesting slow disease progression in our study 
cohort, an effect likely due to 79.9 % of PD cases under anti-parkinsonian treatment at the time of 
the study. While the correlates between clinical motor scales and molecular mechanisms like 
DNA methylation are not determined, the slow disease progression may result into smaller 
changes in methylation. Future studies including additional longitudinal points and spanning 
longer periods of time may detect additional epigenetic changes relevant to pathology.  
In summary, we present evidence demonstrating that changes to the methylome in PD are 
detectable in blood; change over time; and in many cases reflect cellular processes implicated in 
ongoing neurodegeneration in the brains of PD patients. In particular, the longitudinal sampling of 
our study emphasizes that DNA methylation is dynamic in PD and that common PD medication, 
including levodopa formulations and COMT-inhibitors impact methylation. Taken in all, these 
studies support the potential of blood DNA methylation as an epigenetic biomarker of disease, 
although additional profiling of large longitudinal cohorts is needed to complete the 
characterization of DNA methylation changes during the onset and progression of Parkinson’s 
disease. 
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CHAPTER 3 
DNA METHYLATION AND EXPRESSION PROFILES OF WHOLE BLOOD IN PARKINSON’S 
AND ALZHEIMER’S DISEASES 
INTRODUCTION 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are the two most common age-
related neurodegenerative diseases(Mayeux and Stern 2012; Tysnes and Storstein 2017), 
collectively afflicted over 6.5 million people in the U.S. alone.  
PD characteristically manifests as overt motor defects following the destruction of 
dopaminergic neurons in the substantia nigra and is pathologically associated with α-synuclein 
protein aggregation into intracellular cytoplasmic inclusions, termed Lewy bodies. This brain 
pathology is proposed to result from initial insults via olfaction or in the gut, with retrograde 
trafficking into affected brain regions (Hawkes et al. 2009; Planken et al. 2017). 
Neurodegeneration occurs primarily in dopaminergic neurons of the substantia nigra, but Lewy 
body pathology occurs in limbic and cortical areas as PD progresses(Mattila et al. 2000). 
Currently, PD diagnosis is predominantly based on clinical manifestations of the disease, 
namely by the findings of tremor, rigidity, and bradykinesia. Extrastriatal, non-motor symptoms of 
PD, including cognitive problems, apathy, depression, anxiety, hallucinations, and psychosis as 
well as sleep disorders, fatigue, autonomic dysfunction, sensory problems, and pain can begin 
years before diagnosis, accompany the course of disease progression, and are major factors in 
reduced quality of life(Barone et al. 2009). Clinical diagnostic accuracy of 53% in these early 
stages of PD, is unacceptably low(Mehta and Adler 2016). Ongoing prevention therapy research 
currently underway(Olanow and Schapira 2013), would be greatly facilitated by increased 
diagnostic accuracy of early stage PD. Indeed, currently on average, over half of all dopaminergic 
neurons in the substantia nigra are already lost by the time of accurate clinical 
diagnosis(Delenclos et al. 2016), making prevention approaches problematic. A combination of 
multiple biomarker approaches as a diagnostic panel could accelerate improvements in early 
diagnostic accuracy. This will be important in pushing the point at which diagnosis, or high risk 
prediction, can be made to an even earlier time point in pre-motor prodromal stages. To this end, 
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multiple pre-motor biomarkers are actively being investigated for their potential to identify early-
stage PD or patients at risk for developing PD (Haas et al. 2012), including clinical measures 
(rapid eye movement behavior disorder (RBD), olfactory deficits, mood disorders); molecular 
measures (α-syn in cerebrospinal fluid and blood); and brain imaging. 
Epigenetic factors, which can be modified by both environment and ongoing disease 
processes, are emerging as important components of neurodegenerative diseases, including 
PD(Pavlou and Outeiro 2017). The dynamic process of DNA methylation is one of the most 
commonly studied epigenetic regulators in human disease. Addition of a methyl group primarily 
occurs on cytosine bases that are next to guanines, referred to as CpG sites, and it occurs to a 
much lesser extent on cytosines next to other bases(Messerschmidt et al. 2014). Initial 
hypotheses regarding methylation function were mainly centered around the polarizing effects 
that it can confer on gene expression (e.g., imprinting). However, the effects of DNA methylation 
on gene expression are far more nuanced and can be heavily context-dependent.  
Hypomethylation of the α-synuclein gene (SNCA) promoter region has been reported in 
substantia nigra of PD patients in some studies(Jowaed et al. 2010; Matsumoto et al. 2010), yet 
not replicated in others (Richter et al. 2012; Guhathakurta et al. 2017). Epigenomic changes 
associated with other genes, including hypomethylation of NPAS2(Lin et al. 2012) and 
CYP2E1(Kaut et al. 2012);  and hypermethylation of PGC1-α(Su et al. 2015) and the H1 
haplotype of Tau (MAPT)(Coupland et al. 2014), have also been implicated in PD. More recently, 
epigenome wide association studies (EWAS) have identified concordant dysregulation of the 
methylome in brain and blood of PD patients(Masliah et al. 2013). Two additional EWAS have 
identified sites of altered DNA methylation throughout the genome in blood samples of PD 
patients versus controls(Moore et al. 2014; Chuang et al. 2017), suggesting that PD is associated 
with altered methylation that can be detected in peripheral blood samples and raising the 
possibility that a peripheral epigenetic biomarker of PD could be possible. 
The primary functional consequence of DNA methylation is a resulting effect on 
regulation of gene expression. Thus altered DNA methylation would be predicted to alter mRNA 
expression levels as well. In the current work, we profile the methylome of whole blood from PD, 
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AD, and healthy age-matched controls using the Illumina Infinium 450K Human Methylation 
beadchip and also perform mRNA-seq on the same blood samples to identify DNA methylation 
loci that are associated with differential gene expression in each disease. Findings provide 
information about coordinate epigenome-wide regulation of gene expression across PD and AD. 
 
METHODS 
 
Patient demographics 
 
 All studies were approved by Institutional Review Boards in accordance with the 
Declaration of Helsinki.  Informed consent was obtained from all participants. Study participants 
completed a comprehensive neurologic examination and have received a clinical diagnosis of AD 
(n=10), PD (n=15), or Control (CON; n=15).  PD, AD, and CON patients were 27%, 50%, and 
53% female, respectively. Average ages per group at sample collection were 68 (CON) and 72 
years old (PD and AD). PD individuals were cognitively normal based on the Kokmen Short Test 
of Mental Status with a score of 37 or greater.  
Blood collection, DNA & RNA extraction 
 Peripheral blood was collected from patients using standard venipuncture techniques into 
PreAnalytiX PAXgene blood DNA and RNA tubes. Vacutainers were inverted several times and 
stored at -80°C. Samples were isolated from peripheral leukocytes according to manufacturer 
instructions with the PAXgene DNA or RNA isolation kits (Qiagen). Isolated samples were stored 
at -20°C.  
Methylation array procedure 
 We examined methylation using Illumina Infinium HumanMethylation450K Beadchips per 
the manufacturer protocol. Genomic DNA samples were first bisulfite converted using the Zymo 
EZ DNA methylation kit, per manufacturer instructions with the alternative incubation conditions 
specified in the protocol for compatibility with the Illumina Infinium Methylation Assays. Bisulfite 
converted DNA was amplified, fragmented, precipitated, resuspended, and hybridized to 
beadchips following the manual protocol. Fluorescent staining was automated with Illumina’s 
Tecan system. The chips were coated and vacuum-dried for preservation before scanning to 
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retrieve fluorescence intensity data, representing methylated or unmethylated positions, with 
Illumina’s iScan. 
Methylation analysis 
 Raw intensity files were processed with the R package, minfi. The data were normalized 
using the “functional normalization” method, sex chromosomes and positions at known SNPs 
were excluded from further analysis. Figure 9 shows sample clustering following removal of these 
positions. Biologically typical differential methylation between males and females is significant 
enough to skew any other analyses that should ideally be performed without that bias as much as 
possible. Single position differential methylation and region-wise differential methylation were 
measured with the R packages, limma(Ritchie et al. 2015) and DMRcate(Peters et al. 2015b), 
respectively. The model design input to limma was ~0+Group+Slide, using AD vs. controls and 
PD vs. controls as the desired contrasts, and beadchips (“Slide”) as an additional variable. The 
linear model was fit to the data and the empirical Bayes function was applied to calculate 
differentially methylated probes. Peripheral blood cell-type counts were estimated using the 
function available in the minfi package. Only one patient sample was excluded from analysis as a 
PCA outlier for a disproportionately high b-cell balance. Cell-type composition PCAs are shown in 
figure 10. 
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Figure 9. Group clustering following removal of sex chromosomes and positions at known 
SNPs. 
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RNA sequencing (RNAseq) & Expression analysis 
 mRNA was sequenced using the Illumina TruSeq RNA Library Prep kit on the HiSeq 
2000 platform following the manufacturer’s protocol. Paired end RNA read transcripts were 
quantified with Kallisto(Bray et al. 2016), a program based on pseudoalignment. Kallisto’s 
differential expression analysis companion is Sleuth, which outputs beta values as the measure 
for differential expression. This is similar to fold change, and different than the beta values 
reported for differential methylation output. 
Integrated analysis: Combined p-values 
 Significance values for genes nearest to differentially methylated positions (DMPs) and 
differentially expressed (DE) genes were combined to reveal genes that were most significantly 
different in case vs. control(Ozer and Sezerman 2015). This method is widely used and was first 
described in Statistical Methods for Research Workers by R.A. Fisher(Fisher 1930) as a method 
for obtaining a single test of significance for a set of aggregated data based on the product of the 
individually observed probabilities. The basis is that the probability of rejecting the global null 
hypothesis is related to the intersection of each individual test probability(Winkler 2012). 
Integrated analysis: meQTL 
 We identified associations between differentially methylated loci and changes in gene 
expression at those sites using the MatrixEQTL(Shabalin 2012) package in R. Methylation 
quantitative trait loci (meQTL) were measured in both cis (<10,000 bp from a gene) and trans 
(>10,000 bp from a gene). 
GO enrichment 
 Enrichment analysis was performed with the R package topGO(Alexa and Rahnenfuhrer 
2018), by checking significant DMPs and meQTLs against our unfiltered gene expression list as 
the gene universe. Simple gene ontology analysis for prominent pathways in gene lists was done 
with GeneMANIA(Montojo et al. 2010), a web-based software. 
Figure 10. Cell-type composition principle component analysis (PCA) plots for AD and PD. 
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Functional network analysis 
 A supervised functional network analysis was performed using an algorithm called 
Functional Epigenetic Modules (FEM), developed by Jiao et al., which identifies gene modules 
from protein-protein interaction networks that exhibit dysregulation in both DNA methylation and 
gene expression(Jiao et al. 2014). 
 
RESULTS 
Differentially Methylated Positions in Alzheimer’s Disease patients. 
 There were a variety of biological pathways related to differentially methylated positions 
in AD, including cyclase and lyase activity, many metabolic and ion homeostasis processes. 
Aberrant adenylate cyclase activity was previously reported in AD(Kelly 2018). Table 11 shows 
the top differentially methylated positions that are unique to the AD dataset. 
 Syntrophin Gamma 1 (SNTG1; ch.8.1157478F, logFC = 2.56, p = 3.55 x 10-3) and 
Activating Transcription Factor 6 (ATF6; cg22522357, logFC = 2.03, p = 5.07 x 10-3) are genes of 
interest near DMPs within the top hypermethylated positions. SNTG1, primarily expressed in the 
brain, is an adapter protein involved in subcellular organization of proteins and neurotrophic 
signaling. A variant of SNTG1 has been associated with a delay of AD onset in patients who also 
carry the PSEN1 E280A mutation(Vélez et al. 2018). ATF6 is a transcription factor that activates 
genes in the unfolded protein response pathway when there is endoplasm reticulum (ER) stress. 
Xu et al. found that overexpression of mesencephalic astrocyte-derived neurotrophic factor 
(MANF) reduced ATF6 levels, along with other ER stress molecules, in an Aβ42 toxicity reduction 
study(Xu et al. 2019). 
 Hypomethylated positions are near genes related to several cell transport processes 
including ATP synthesis proton transport, transmembrane activity, and purine-containing 
biosynthesis. Calcitonin Related Polypeptide Alpha (CALCA; cg24136292, logFC = -3.02, p = 
5.44 x 10-4) and Ataxin 1 (ATXN1; cg19300401, logFC = -2.78, p =1.27 x 10-3) are genes of 
interest near hypomethylated positions. CALCA is a regulatory neuropeptide involved in activation 
of PKA which has been shown to upregulate α-subunit of the acetylcholine receptor (AChR) in the 
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brain, which is a target of AD therapy research(Vallés et al. 2014; Singh et al. 2017). ATXN1 
affects amyloid precursor protein (APP) protein levels and may be a risk factor for late onset AD; 
additionally, mutations in ATXN1 lead to spinocerebellar ataxia type 1 (SCA1)(Zhang et al. 2010).  
 
 
 
 
 
 
 
 
 
Figure 11. AD Manhattan plot of global differential methylation significance. 
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Probe Position 
Fold 
Change 
(log2) 
P-Value Target Gene Name 
Position 
in Target 
Gene 
Nearest Gene 
Hypermethylated  
cg07056794 chr9:139318309 3.18 6.23 x 10-3   INPP5E 
cg18339359 chr8:23423757 2.97 7.55 x 10-3 SLC25A37 Body ENTPD4 
cg14655569 chr9:95473718 2.86 1.61 x 10-3 BICD2 3'UTR BICD2 
cg22627029 chr6:32520615 2.81 6.77 x 10-3 HLA-DRB6 Body HLA-DQA1 
cg14926231 chr2:906044 2.61 4.16 x 10-3 C2orf90 TSS200 LINC01115 
cg21223191 chr6:32583741 2.56 2.59 x 10-3   HLA-DQA1 
ch.8.1157478F chr8:52618305 2.56 3.55 x 10-3 PXDNL Body SNTG1 
cg19353052 chr12:113516445 2.51 1.05 x 10-3 DTX1 Body DTX1 
cg24307368 chr11:107582884 2.43 3.39 x 10-3 SLN TSS200 SLN 
cg05161773 chr17:75378036 2.15 9.80 x 10-3 SEPT9 5'UTR; Body SEPT9 
cg22522357 chr1:161872770 2.03 5.07 x 10-3 ATF6 Body OLFML2B 
Hypomethylated  
cg22777560 chr5:177612982 -3.44 8.97 x 10-3 GMCL1L Body HNRNPAB 
cg01778345 chr1:118427435 -3.39 6.13 x 10-3 GDAP2 Body GDAP2 
cg02978201 chr16:11374865 -3.35 8.88 x 10-3 PRM1 Body PRM1 
cg27187580 chr3:112927486 -3.28 6.18 x 10-4   CFAP44 
cg24136292 chr11:15180922 -3.02 5.44 x 10-4 INSC Body CALCA 
cg19300401 chr6:16962712 -2.78 1.27 x 10-3   ATXN1 
cg00256329 chr17:724374 -2.76 1.37 x 10-3 NXN Body MRM3 
cg22304519 chr2:227560785 -2.61 5.81 x 10-3   IRS1 
cg26813483 chr13:111980537 -2.54 3.02 x 10-3 C13orf16 Body TEX29 
cg19475903 chr6:39271655 -2.53 1.62 x 10-3 KCNK17 Body KCNK17 
cg10771931 chr19:34972145 -2.50 1.58 x 10-3 WTIP TSS1500 SCGB1B2P 
cg18203203 chr12:113939171 -2.39 4.24 x 10-3   SDSL 
cg18096251 chr5:2205553 -2.36 2.52 x 10-3   IRX4 
cg15876198 chr14:95106927 -2.25 2.48 x 10-3 SERPINA13 TSS200 SERPINA13P 
 
 
 
 
 
 
Table 11. Top differentially methylated positions in AD. 
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Differentially Methylated Positions in Parkinson’s Disease patients. 
 Pathways among differentially methylated positions in the PD cohort are primarily 
involved in antigen presentation and T-cell activation, and processes related to the endoplasmic 
reticulum. Differentially methylated positions are presented in table 12. 
 HCN2 (cg10662395, logFC = 2.11, p = 9.34 x 10-3) and Trafficking Kinesin Protein 1 
(TRAK1; cg24284460, logFC = 2.00, p = 5.16 x 10-4) are genes of interest near hypermethylated 
positions. HCN2 is one isoform of a hyperpolarization-activated cyclic nucleotide-gated (HCN) 
channel with a role in the transmission of neuropathic and inflammatory pain. HCN channels 
control oscillatory activity of dopaminergic neurons in the midbrain and their dysfunction has been 
proposed to play a role in PD pathogenesis(DiFrancesco and DiFrancesco 2015). TRAK1 is 
involved in endosome to lysosome trafficking and regulation of mitochondrial fusion. A mutation 
leading to truncated TRAK1 causes hypertonia in mice, which initiated further study of this gene 
in the context of neurological disorders, including PD; it is also implicated in several cancers and 
childhood absence epilepsy(Lee et al. 2018). 
 Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA4; cg05092371, logFC = -2.96, p = 
1.42 x 10-3) and Epidermal Growth Factor Receptor Pathway Substrate 15 (EPS15; cg06751175, 
logFC = -2.05, p = 5.17 x 10-3) are near two of the top hypomethylated positions. CTLA4 is an 
immunosuppressive modulator of T-cell activation. Mkhikian et al. studied the interplay between 
dysregulated loss of N-glycosylation and the subsequent loss of CTLA4 cell surface expression in 
concert with reduced T-cell activation thresholds in the pathology of multiple sclerosis(Mkhikian et 
al. 2011). CTLA4 was also shown to contribute to increased survival of neural cell porcine 
xenografts delivered to nonhuman primates in a study aimed at improving PD cell transplantation 
therapies(Aron Badin et al. 2016). In 2006, EPS15 was functionally linked to the PD susceptibility 
gene, Parkin, through demonstration that EPS15 is phosphorylated and ubiquitinated in response 
to exposure to epidermal growth factor (EGF), and that EPS15 ubiquitination is mediated by 
parkin, which also showed parkin’s role in trafficking and PI3K-Akt signaling(Fallon et al. 2006). 
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Figure 12. PD Manhattan plot of global differential methylation significance 
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Probe Position 
Fold 
Change 
(log2) 
P-Value Target Gene Name 
Position 
in Target 
Gene 
Nearest 
Gene 
Hypermethylated 
cg21211688 chr9:136403935 2.79 7.27 x 10-3 ADAMTSL2 Body ADAMTSL2 
cg09727210 chr7:2962240 2.76 1.62 x 10-3 CARD11 Body CARD11 
cg13353337 chr22:21336550 2.61 1.03 x 10-3 LZTR1 TSS200 THAP7 
cg00546757 chr5:170845058 2.60 8.29 x 10-3   MIR3912 
cg03329597 chr3:108125523 2.58 2.61 x 10-3 MYH15 Body HHLA2 
cg26264314 chr19:56510965 2.57 3.59 x 10-3 NLRP5 TSS200 NLRP13 
cg10662395 chr19:597635 2.11 9.34 x 10-3 HCN2 Body POLRMT 
cg02249577 chr10:52434778 2.09 6.31 x 10-3   SGMS1 
cg24284460 chr3:42139507 2.00 5.16 x 10-4 TRAK1 Body ULK4 
cg24533989 chr4:42659536 1.95 7.27 x 10-3 ATP8A1 TSS1500 ATP8A1 
cg13452812 chr9:2234921 1.92 8.75 x 10-3   VLDLR-AS1 
cg24166916 chr5:78282669 1.88 9.59 x 10-3 ARSB TSS1500 ARSB 
cg00616572 chr16:10772249 1.87 4.09 x 10-3 TEKT5 Body NUBP1 
Hypomethylated 
cg21046080 chr12:131506092 -4.85 3.63 x 10-4 GPR133 Body STX2 
cg05092371 chr2:204731519 -2.96 1.42 x 10-3 CTLA4 TSS1500 CTLA4 
cg13604933 chr6:40145993 -2.93 1.52 x 10-3   LINC00951 
cg00035449 chr6:169539646 -2.87 6.51 x 10-3   THBS2 
cg14114910 chr9:124924045 -2.75 7.91 x 10-3 MORN5 Body MORN5 
cg26296371 chr6:5442953 -2.72 8.88 x 10-3 FARS2 Body LYRM4 
cg07304760 chr7:127514192 -2.72 2.29 x 10-3 SND1 Body LRRC4 
cg13251750 chr14:94943234 -2.70 2.35 x 10-3 SERPINA9 TSS1500 SERPINA9 
cg13248811 chr4:24796803 -2.63 9.16 x 10-3 SOD3 TSS1500 CCDC149 
cg01324343 chr3:183735012 -2.55 8.36 x 10-4 ABCC5 5'UTR ABCC5 
cg02375258 chr19:52074470 -2.42 3.83 x 10-3 ZNF175 TSS200 ZNF175 
cg00874817 chr16:46824055 -2.35 4.13 x 10-4   C16orf87 
cg24536782 chr8:216659 -2.30 1.91 x 10-3   RPL23AP53 
cg08762424 chr6:31275881 -2.29 1.52 x 10-3   HLA-B 
cg24167747 chr19:54614832 -2.23 3.16 x 10-3 TFPT Body TFPT 
cg24849373 chr8:143376371 -2.21 2.48 x 10-3 TSNARE1 Body LINC00051 
cg07490070 chr2:97505464 -2.11 2.78 x 10-4 ANKRD23 Body CNNM3 
cg03654560 chr5:178266175 -2.10 5.54 x 10-3   AACSP1 
cg15652532 chr2:30669759 -2.09 8.80 x 10-3 LCLAT1 TSS1500 CAPN13 
cg08270148 chr8:914818 -2.06 7.75 x 10-3   ERICH1 
cg06751175 chr1:52083188 -2.05 5.17 x 10-3 OSBPL9 Body; 5'UTR EPS15 
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Differentially Methylated Positions in Alzheimer’s & Parkinson’s Disease patients. 
 Among the overlapping DMPs, present in both PD and AD, two positions near potential 
genes of interest were hypermethylated. Arylsulfatase B (ARSB; cg19547330, AD logFC = 1.49, 
PD logFC = 1.54) is a lysosomal enzyme associated with a lysosomal storage disorder called 
MPS VI. Jansen et al. identified a loss of function variant in ARSB of four PD patients. In the 
same study, RNAi knockdown of the ARSB Drosophila homolog enhanced human a-synuclein 
transgene mediated neurodegeneration in the fly retina(Jansen et al. 2017). The second shared 
gene of interest, Zinc Finger DHHC-Type Containing 17 (ZDHHC17; cg26864661, AD logFC = 
3.10, PD logFC = 2.69), codes for Huntingtin interacting protein 14 (HIP14) and is a highly 
conserved palmitoyl acyltransferase that acts upon many synaptic proteins(Sanders et al. 2016). 
It affects nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2)-dependent axon survival 
in mouse primary neurons and Drosophila axon extension in vivo(Milde and Coleman 2014). 
 
 
Probe Nearest Gene 
AD Fold 
Change AD P-Value 
PD Fold 
Change PD P-Value 
Hypermethylated 
cg04663285 SIGIRR 1.39 8.67 x 10-3 1.64 1.92 x 10-3 
cg14955916 ZMYND11 1.34 4.51 x 10-3 1.38 2.93 x 10-3 
cg18493115 MOB2 1.75 1.65 x 10-3 1.40 8.43 x 10-3 
cg19547330 ARSB 1.49 3.03 x 10-3 1.54 1.82 x 10-3 
cg24906015 FANCL 2.25 3.35 x 10-3 2.20 3.43 x 10-3 
cg26864661 ZDHHC17 3.10 1.51 x 10-3 2.69 4.20 x 10-3 
cg27468880 GET4 2.49 6.47 x 10-3 3.19 5.81 x 10-4 
Hypomethylated 
cg00587941 RASA3 -2.61 3.73 x 10-3 -2.59 3.34 x 10-3 
cg05270750 PRDM7 -1.06 1.70 x 10-3 -1.29 1.81 x 10-4 
cg05394663 WNT3A -1.13 2.88 x 10-3 -1.31 6.06 x 10-4 
cg06295223 GAS8 -1.19 7.78 x 10-4 -1.40 9.34 x 10-5 
cg10765922 HLA-DQA1 -1.09 8.64 x 10-3 -1.11 6.82 x 10-3 
cg15729439 HPS5 -1.37 8.91 x 10-3 -1.33 9.76 x 10-3 
Table 12. Top differentially methylated positions in PD. 
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cg16580391 HLA-DPB2 -1.04 2.56 x 10-3 -1.12 1.08 x 10-3 
cg16611967 GAS8 -1.98 4.08 x 10-3 -2.68 1.66 x 10-4 
cg17553353 GCSAM -1.14 8.36 x 10-4 -1.13 7.05 x 10-4 
cg22730047 CFAP126 -1.26 7.28 x 10-3 -1.80 2.01 x 10-4 
cg27226147 ZNF184 -1.47 6.00 x 10-3 -1.98 3.04 x 10-4 
cg27601198 ORC6 -1.16 9.82 x 10-3 -1.68 3.05 x 10-4 
 
 
Differentially Methylated Regions in Alzheimer’s Disease patients. 
 Pathways significantly involved with differentially methylated regions (DMRs), where at 
least two CpG positions are within 1000 nucleotides of each other, are associated with 
neurotrophin and tyrosine kinase (TRK) signaling, retinoic acid receptor signaling, vitamin 
metabolism, and transcription repression. 
 Five regions were hypermethylated and 14 were hypomethylated at FDR ≤ 0.001 (Table 
14). Vault RNA 2-1 (VTRNA2-1; region start = chr5:135414858, probes in DMR = 20, fold change 
= 0.128, FDR = 6.88 x 10-6) is near a hypermethylated region of interest. Its hypermethylation is 
associated with several cancers(Romanelli et al. 2014) and upregulation has been proposed as 
an early event in Parkinson’s disease that contributes to neuronal dysfunction(Minones-Moyano 
et al. 2013).  
 Dual Specificity Phosphatase 22 (DUSP22; region start = chr6:291687, probes in DMR 
=11, fold change = -0.136, FDR = 2.86 x 10-4) is near a hypomethylated region. The promoter of 
DUSP22 was previously found to be hypermethylated in patients with AD, conversely to our 
finding, and the gene is involved in PKA-mediated tau phosphorylation(Sanchez-Mut et al. 2014). 
 
 
 
 
 
Table 13. Top differentially methylated positions in AD and PD. 
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Table 14. Top differentially methylated regions in AD. 
Region Start Width Probes in DMR FDR 
Fold 
Change 
Overlapping 
Promoters Nearest Gene 
Hypermethylated 
chr5:135414858 1756 20 6.88 x 10-6 0.128  VTRNA2-1 
chr6:28945182 326 8 2.33 x 10-4 0.130 LINC01556-001 ZNF311 
chr6:31148332 417 16 2.91 x 10-4 0.095  PSORS1C3 
chr12:132880790 2083 5 3.41 x 10-4 0.087 CHFR-010 GALNT9 
chr6:29648161 932 25 5.19 x 10-4 0.140  ZFP57 
Hypomethylated  
chr6:28874479 892 7 2.04 x 10-6 -0.084  TRIM27 
chr4:184908254 765 9 3.51 x 10-6 -0.085  STOX2 
chr10:1975000 632 4 1.04 x 10-4 -0.083  LINC00700 
chr4:76996414 277 2 1.64 x 10-4 -0.081  ART3 
chr6:291687 1645 11 2.86 x 10-4 -0.136 DUSP22 DUSP22 
chr19:5799340 128 3 5.10 x 10-4 -0.089  DUS3L 
chr1:202171635 1278 7 5.61 x 10-4 -0.096  LGR6 
chr7:1003645 1932 8 5.67 x 10-4 -0.074  COX19;ADAP1 
chr11:3175007 630 4 5.84 x 10-4 -0.071  OSBPL5 
chr1:23886730 1087 4 5.89 x 10-4 -0.077  ID3 
chr19:2546598 470 5 6.54 x 10-4 -0.073  GNG7;GADD45B 
chr14:102676728 567 4 7.90 x 10-4 -0.071  WDR20;MOK 
chr2:32490766 70 2 8.11 x 10-4 -0.073  NLRC4 
chr5:54275155 44 2 9.42 x 10-4 -0.088   ESM1 
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Figure 13. DMRs in AD. (A) VTRNA2-1 and (B) DUSP2. 
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Differentially Methylated Regions in Parkinson’s Disease patients. 
 Pathways related to genes near DMRs in PD are related to digestive tract development 
and several pathways are associated with transcription regulation, including JAK-STAT signaling. 
Implication of the enteric nervous system in the course, or even the etiology of PD makes this 
finding particularly interesting, suggesting that there are digestive tract genes being differentially 
regulated in the context of disease. 
 One region, near Growth Regulating Estrogen Receptor Binding 1 (GREB1; region start = 
chr2:11672761, probes in DMR = 2, fold change = 0.057, FDR = 9.77 x 10-4), was 
hypermethylated at FDR ≥ 0.001. GREB1 is a steroid hormone induced gene that is active in 
breast and prostate cancer cell proliferation, and plays a role in renal disease, but has not 
previously shown associations with neurological disorders(Hodgkinson and Vanderhyden 2014). 
 Six DMRs were hypomethylated, including one near SMAD Family Member 6 (SMAD6; 
region start = chr15:66947066, probes in DMR = 6, fold change = -0.117, FDR = 3.57 x 10-5). 
SMAD6 is involved in the recruitment of A20 de-ubiquitinating enzyme to E3 ubiquitin ligases 
allowing for negative feedback following toll-like receptor (TLR) activation during innate immune 
responses. TLRs and the propagation of chronic pro-inflammatory responses are heavily and 
broadly implicated in neuropathogenesis(Kinsella et al. 2018). 
 
Region Start Width Probes in DMR FDR 
Fold 
Change Nearest Gene 
Hypermethylated           
chr2:11672761 600 2 9.77 x 10-4 0.057 GREB1 
Hypomethylated           
chr12:116043958 75 3 8.80 x 10-6 -0.126 MED13L;MIR620 
chr15:66947066 552 6 3.57 x 10-5 -0.117 SMAD6 
chr6:166232637 505 5 3.65 x 10-4 -0.114 LINC00473 
chr11:65359521 989 6 3.65 x 10-4 -0.107 EHBP1L1 
chr11:18477153 983 10 5.99 x 10-4 -0.090 LDHAL6A 
chr8:215923 866 6 9.27 x 10-4 -0.165 ZNF596 
 
 
Table 15. Top differentially methylated regions in PD. 
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Differentially Methylated Regions in Alzheimer’s & Parkinson’s Disease patients. 
 Alkaline phosphatase (ALPL; region start = chr1:21900987, probes in DMR = 3, fold 
change = -0.06, AD FDR = 6.95 x 10-5, PD FDR = 1.43 x 10-5) is near a hypomethylated DMR in 
AD and PD. Increased ALPL activity has been associated with central nervous system injury and 
the neurotoxic effect of extracellular tau protein in AD(Vardy et al. 2012). Serpin Family B 
Member 9 (SERPIN9B; region start = chr6:2891973, probes in DMR = 5, AD fold change = 0.07, 
PD fold change = 0.05) is hypermethylated and may contribute to autoinflammatory disease 
through incomplete caspase-1 inhibition resulting in uncontrolled interleukin-1b inhibition(Burgh et 
al. 2016). One study found an association between increased expression of SERPIN9B in 
females with Alzheimer’s disease to be associated with greater amyloidosis(Deming et al. 2018). 
Figure 14. SMAD6 DMR in PD. 
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Differential Expression in Alzheimer’s Disease. 
 Genes differentially expressed in AD are largely involved with protein translation, driven 
by underexpressed genes. Cytokine production is upregulated. 
 CCS (beta = 2.00, p = 1.32 x 10-3) and Integrin Subunit Beta 2 (ITGB2; beta = 0.94, p = 
1.69 x 10-3) were overexpressed in our results. Copper chaperone for super oxide dismutase 
(CCS) binds to the intracellular domain of Beta-Secretase 1 (BACE1) and to X11a, both of which 
Table 16. Top differentially methylated regions in AD and PD. 
Region Start Width Probes in DMR AD FDR 
AD Fold 
Change PD FDR 
PD Fold 
Change 
Overlapping 
Promoters 
Nearest 
Gene 
Hypomethylated 
chr1:21900987 274 3 6.95 x 10-5 -0.06 1.43 x 10-5 -0.06  ALPL 
chr1:26880207 1122 7 2.93 x 10-4 -0.03 7.18 x 10-3 -0.03  RPS6KA1 
chr1:38412519 300 6 4.07 x 10-3 -0.02 8.10 x 10-3 -0.02  INPP5B 
chr10:4867773 1316 13 3.08 x 10-8 -0.06 5.92 x 10-5 -0.05  AKR1E2 
chr11:64980819 778 7 2.92 x 10-10 -0.05 3.01 x 10-3 -0.03  SLC22A20P 
chr11:67069814 2072 15 5.52 x 10-11 -0.03 2.60 x 10-12 -0.02  SSH3 
chr11:89867385 592 10 3.64 x 10-4 -0.04 4.16 x 10-3 -0.04 RP11-81M19.3-001 NAALAD2 
chr12:122018177 2837 21 1.09 x 10-10 -0.03 2.49 x 10-3 -0.02 BCL7A, RP11-87C12.5 KDM2B 
chr16:90143751 1038 6 6.51 x 10-7 -0.08 2.83 x 10-12 -0.10 RNU6-355P-201 PRDM7 
chr16:90172237 783 5 7.53 x 10-4 -0.07 2.51 x 10-3 -0.06 FAM157C-201 PRDM7 
chr17:41923945 633 12 4.29 x 10-3 -0.02 7.12 x 10-4 -0.02  CD300LG 
chr19:14049018 1076 7 1.14 x 10-4 -0.03 1.83 x 10-4 -0.03  PODNL1 
chr2:242808427 481 5 3.85 x 10-3 -0.07 1.95 x 10-4 -0.08  RTP5 
chr20:1927546 366 4 3.62 x 10-3 -0.02 1.88 x 10-3 -0.02  SIRPA 
chr20:20036653 498 6 1.65 x 10-3 -0.05 2.24 x 10-4 -0.05 CRNKL1 CRNKL1 
chr22:23522307 1830 12 2.10 x 10-4 -0.02 8.55 x 10-3 -0.01  BCR 
chr22:45071340 1826 11 9.30 x 10-6 -0.03 1.09 x 10-3 -0.02  PRR5 
chr3:111717534 1032 12 1.40 x 10-5 -0.05 6.14 x 10-3 -0.04  TAGLN3 
chr4:74864165 1338 9 1.62 x 10-5 -0.03 8.09 x 10-6 -0.03  CXCL5 
chr6:30623775 995 15 8.47 x 10-8 -0.03 2.91 x 10-3 -0.02  DHX16 
chr6:44186914 761 12 9.02 x 10-9 -0.01 2.08 x 10-9 -0.01  SLC29A1 
chr7:27260102 484 6 1.49 x 10-4 -0.03 3.88 x 10-7 -0.03  HOTTIP 
Hypermethylated 
chr10:459697 272 3 3.94 x 10-3 0.08 5.38 x 10-3 0.08  DIP2C 
chr11:44626708 43 2 2.92 x 10-4 0.03 3.20 x 10-3 0.03  CD82 
chr16:87734816 909 7 2.46 x 10-8 0.03 1.12 x 10-3 0.02  KLHDC4 
chr6:2891973 180 5 1.07 x 10-6 0.07 8.95 x 10-3 0.05  SERPINB9 
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interact with APP. CCS homozygous knockout in mouse neurons resulted in greater levels of AB 
production along with increased processing of APP at the BACE1 site(Gray et al. 2010). ITGB2 
has been previously identified to be highly associated with AD onset(Zhang et al. 2013) and 
another RNAseq study assigned this gene as part of a module of therapeutic candidates for 
cognitive resilience in early stages of AD using a pre-symptomatic AD mouse model(Neuner et al. 
2019). 
Gene Beta P-Value Transcript 
Overexpressed 
PRAM1 1.02 1.18 x 10-3 ENST00000600262.1 
CD2BP2 1.79 1.32 x 10-3 ENST00000564525.1 
CCS 2.00 1.32 x 10-3 ENST00000310190.8 
AMPD2 1.42 1.61 x 10-3 ENST00000528270.5 
ITGB2 0.94 1.69 x 10-3 ENST00000302347.9 
KLHL21 1.31 1.74 x 10-3 ENST00000496707.5 
IQGAP1 0.99 1.80 x 10-3 ENST00000268182.9 
PQLC3 2.28 1.82 x 10-3 ENST00000441908.6 
SF3A1 1.99 1.99 x 10-3 ENST00000444440.1 
ACTG1 2.66 2.07 x 10-3 ENST00000573283.5 
Underexpressed  
C16orf74 -1.07 1.03 x 10-3 ENST00000602675.5 
ODF3B -2.01 1.07 x 10-3 ENST00000403326.5 
ZNF592 -2.48 1.27 x 10-3 ENST00000299927.4 
PTRHD1 -1.23 1.30 x 10-3 ENST00000467797.1 
SNHG8 -0.83 1.42 x 10-3 ENST00000602414.5 
QARS -1.63 1.64 x 10-3 ENST00000637281.1 
RPL23A -2.01 1.69 x 10-3 ENST00000496182.5 
MED25 -2.99 1.80 x 10-3 ENST00000618715.4 
PSME2 -1.41 1.80 x 10-3 ENST00000560410.5 
PIEZO1 -1.64 2.05 x 10-3 ENST00000472168.1 
 
Differential Expression in Parkinson’s Disease. 
 Genes that are differentially expressed are involved in innate immune responses, 
primarily indicated by genes involved in type I interferon signaling, which is driven by 
underexpressed genes. Overexpressed genes are involved in RAS signaling, implicating cell 
growth and division. 
Table 17. Differentially expressed genes in AD. 
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 Serine/Arginine Repetitive Matrix 2 (SRRM2; beta = -1.97, p = 2.24 x 10-2) was 
underexpressed in our results and was previously reported to be alternatively spliced in PD 
resulting in lowered expression of the long isoform and higher expression of the short(Fu et al. 
2013). SRRM1 was alternatively spliced in our previous RNA-seq PD brain study(Henderson-
Smith et al. 2016) 
Gene Beta P-Value Transcript 
Overexpressed       
MORC3 2.27 1.01 x 10-2 ENST00000400485.5 
GOLM1 2.20 1.01 x 10-2 ENST00000388712.7 
NCOA1 2.14 1.12 x 10-2 ENST00000348332.7 
SLC43A3 1.93 1.14 x 10-2 ENST00000395124.5 
CANX 2.61 1.24 x 10-2 ENST00000638706.1 
PPP1R18 2.03 1.49 x 10-2 ENST00000615527.1 
VCPKMT 1.81 1.66 x 10-2 ENST00000491402.5 
PPP2R5D 2.03 1.77 x 10-2 ENST00000485511.5 
MBNL1 1.90 1.89 x 10-2 ENST00000497971.1 
DYSF 2.22 2.19 x 10-2 ENST00000258104.7 
Underexpressed       
GYS1 -1.98 1.02 x 10-2 ENST00000263276.6 
HLA-B -3.04 1.08 x 10-2 ENST00000639001.1, ENST00000639564.1 
FHL3 -2.04 1.19 x 10-2 ENST00000485803.5 
SPNS1 -2.06 1.48 x 10-2 ENST00000323081.12 
CCL5 -2.18 1.60 x 10-2 ENST00000605140.5, ENST00000618639.4 
ELF4 -2.21 1.77 x 10-2 ENST00000615377.4 
HLA-B -2.41 1.83 x 10-2 ENST00000462100.1 
HLA-B -2.02 1.91 x 10-2 ENST00000494335.5 
AP2M1 -1.96 2.07 x 10-2 ENST00000461733.5 
SRRM2 -1.97 2.24 x 10-2 ENST00000573692.1 
 
Differential Expression in Alzheimer’s & Parkinson’s Disease patients. 
 Cathepsin D (CTSD) is a lysosomal protease that is overexpressed in PD and AD. It has 
previously been studied in the context of both diseases, as well as for its involvement in 
childhood-onset neurodegenerative disorders(Cermak et al. 2016; Kettwig et al. 2018). It was 
determined to be a candidate PD susceptibility gene by Robak et al. whose study highlighted the 
Table 18. Differentially expressed genes in PD. 
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connection between PD and lysosomal storage disorders, e.g., Gaucher Disease(Robak et al. 
2017). 
 Sequestosome 1 (SQSTM1) encodes the p62 scaffold protein that binds autophagy 
specific markers, including ubiquitinated proteins, in addition to possessing functional domains 
involved in inflammation and oxidative stress(Ma et al. 2019). It is also involved in NF-κB 
activation(Sivandzade et al. 2019). 
 NUMB, Endocytic Adaptor Protein (NUMB) is known and studied for a variety of 
functions, including as an indirect suppressor of NOTCH signaling, an endocytic adapter in 
intracellular trafficking, lysosomal regulation, and autophagy modulation(Sun et al. 2017). It was 
also studied for its role in APP processing and γ-secretase activity related to Vitamin D receptors 
and other neuronal membrane proteins(Dursun and Gezen-Ak 2017).  
 Using a cell line with enhanced γ-secretase activity, Magold et al. found that uridine 
phosphorylase (UPP1) was the top overexpressed gene in their profiling experiment. UPP1 is an 
enzyme involved in processing uridine, which is crucial for membrane biosynthesis as well as 
DNA and RNA. Oral administration of uridine has been used to improve AD phenotypes(Magold 
et al. 2009).  
 
Gene AD Beta AD P-Value PD Beta PD P-Value Transcript 
Overexpressed 
YTHDF3 2.76 3.71 x 10-3 3.36 1.27 x 10-4 ENST00000539294.5 
PPP1R18 3.13 2.47 x 10-3 2.56 7.06 x 10-3 
ENST00000399199.7, 
ENST00000449705.6, 
ENST00000451544.6 
PPP1R18 2.69 3.02 x 10-3 2.28 6.44 x 10-3 
ENST00000274853.7, 
ENST00000437121.2, 
ENST00000443517.2 
CTSD 2.55 4.24 x 10-3 2.19 7.65 x 10-3 ENST00000636571.1 
NUMB 2.40 3.33 x 10-3 2.05 6.44 x 10-3 ENST00000359560.7 
LMBRD1 2.12 3.35 x 10-3 2.05 2.05 x 10-3 ENST00000472827.1 
APP 2.77 1.33 x 10-4 1.90 4.46 x 10-3 ENST00000346798.7 
CHD4 2.19 2.19 x 10-3 1.78 7.05 x 10-3 ENST00000544040.5 
SQSTM1 1.63 7.70 x 10-3 1.65 3.50 x 10-3 ENST00000626660.1 
CD14 2.10 1.24 x 10-4 1.60 1.48 x 10-3 ENST00000498971.6 
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FBXO11 1.73 5.35 x 10-3 1.57 6.18 x 10-3 ENST00000403359.7 
PISD 1.64 3.25 x 10-3 1.36 7.90 x 10-3 ENST00000491342.1 
BAHD1 1.47 7.36 x 10-3 1.35 7.76 x 10-3 ENST00000416165.5 
HERC1 1.05 9.26 x 10-3 1.00 7.14 x 10-3 ENST00000561348.1 
CMTM1 1.27 1.77 x 10-3 1.00 7.99 x 10-3 ENST00000533953.5 
SERPINA1 1.26 1.55 x 10-4 0.99 1.20 x 10-3 ENST00000557492.5, ENST00000629092.2 
Underexpressed 
QARS -3.29 5.85 x 10-5 -2.53 7.96 x 10-4 ENST00000414533.5 
UPP1 -1.88 6.98 x 10-3 -1.84 4.19 x 10-3 ENST00000417464.6 
 
Integrated Analysis 
 Differential methylation and differential expression datasets were queried with several 
integrated methods:  the combined  p-value approach, methylation quantitative loci analysis, and 
functional epigenetic module searching. We also looked for genes that were alternatively spliced 
from our integrated lists. 
 Since the effect of DNA methylation is highly context dependent, we did not limit our 
filtering to inverse relationships (e.g., high methylation and low expression). The combined p-
value tables (20-22) show that many genes are positively associated and contextually varied, as 
expected. The DMP tables (10-12) show the CpG probe positions relative to the CpG island 
associated with that probe, the location of which can be near or far from the probe itself. 
Integrated Analysis: Combined p-values for Alzheimer’s Disease. 
 Immune and inflammatory responses are the top pathways in the combined p-value AD 
dataset. Genes near DMPs that were also differentially expressed were also enriched for 
transmembrane transport and transport to the ER. Several of the top genes that were 
differentially expressed with nearby differentially methylated CpG sites have been previously 
reported for their relationships to AD-associated processes.  
 Beta tubulin (TUBB) was overexpressed in our results and two DMPs were nearest to this 
gene, one hypermethylated and one hypomethylated.  
Table 19. Differentially expressed genes in AD and PD. 
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 Hypericin imparts anti-inflammatory effects and can inhibit transcription of pro-
inflammatory cytokines induced by oligomeric Aβ42 in vitro and in vivo(Zhang et al. 2016). One of 
hypericin’s targets is Myocardin Related Transcription Factor A (MKL1), which is a nuclear 
cofactor recruited by p65 of the NF-κB complex and it was hypermethylated and underexpressed 
in our results (methylation fold change = 0.83, expression beta = -1.90, pcombined = 4.21 x 10-4). 
 SQSTM1 is involved in autophagy and was introduced in the shared AD & PD DE hits 
section of our results. Two different hypomethylated DMPs were near an overexpressed 
transcript (methylation fold change = -0.49 & -0.44, expression beta = 1.63, pcombined = 4.49 x 10-5 
& 6.8 x 10-5). APP was also hypomethylated and overexpressed in our results (methylation fold 
change = -0.59, expression beta = 2.77, pcombined = 6.85 x 10-6). 
 
Gene Transcript Probe P-Val Combined 
Methylation 
Fold 
Change 
Expression 
Beta 
Probe 
Position 
Relative 
to Island 
TMEM176B ENST00000429904.6 cg14909495 3.02 x 10-7 -0.30 -3.06 OpenSea 
DDX24 ENST00000553400.1 ,ENST00000629321.1 cg06992688 4.32 x 10
-6 -0.58 -1.70 N_Shore 
NAPA ENST00000594001.5 cg23314866 6.13 x 10-6 -0.49 -1.95 N_Shore 
AOAH ENST00000491444.5 cg25983531 2.24 x 10-5 -0.60 -1.49 OpenSea 
MKRN1 ENST00000480552.5 cg19494591 3.71 x 10-5 -0.33 -1.05 N_Shelf 
TUBB ENST00000383564.8 cg05978527 3.74 x 10-5 0.25 4.33 S_Shore 
NELFA ENST00000467661.5 cg17584633 3.96 x 10-5 -0.21 -1.85 N_Shelf 
Hypermethylated & Underexpressed 
ATP5O ENST00000290299.6 cg27037013 2.03 x 10-5 0.60 -0.52 OpenSea 
CD3D ENST00000300692.8 cg24612198 4.22 x 10-5 0.54 -0.61 OpenSea 
CD8B ENST00000393759.6 cg22999502 1.16 x 10-5 0.44 -1.72 OpenSea 
DTX1 ENST00000547974.5 cg19353052 1.08 x 10-4 2.51 -0.62 S_Shore 
ADPGK ENST00000569693.5 cg03950246 4.16 x 10-4 0.67 -1.48 N_Shore 
MKL1 ENST00000620651.4 cg25276892 4.21 x 10-4 0.83 -1.90 OpenSea 
Hypomethylated & Overexpressed 
APP ENST00000346798.7 cg14414154 6.85 x 10-6 -0.59 2.77 N_Shelf 
IER3 ENST00000383560.4 cg06126421 1.49 x 10-5 -0.69 2.97 OpenSea 
CD2BP2 ENST00000564525.1 cg05099952 2.14 x 10-5 -0.49 1.79 S_Shore 
IER3 ENST00000383560.4 cg14753356 2.49 x 10-5 -0.58 2.97 OpenSea 
TUBB ENST00000383564.8 cg16137928 2.67 x 10-5 -0.41 4.33 OpenSea 
CDC42EP3 ENST00000457889.1 cg26458748 2.80 x 10-5 -0.70 1.94 OpenSea 
TUBB ENST00000383564.8 cg00985729 3.12 x 10-5 -0.44 4.33 S_Shore 
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SQSTM1 ENST00000626660.1 cg08299521 4.49 x 10-5 -0.49 1.63 OpenSea 
SQSTM1 ENST00000626660.1 cg01152073 6.80 x 10-5 -0.44 1.63 N_Shore 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Integrated Analysis: Combined p-values for Parkinson’s Disease. 
 Combined p-value analysis of genes nearest DMPs that are also differentially expressed 
show that apoptosis, autophagy, and cell division are the main pathways active in both datasets.  
Genes near differentially methylated positions that were also differentially expressed were 
enriched for stress granule assembly, response to cold, and bone morphogenesis. When 
reducing the results to genes that are inversely related, the prominent pathways in the 
hypomethylated and overexpressed set are involved in RNA processing and splicing, which was 
made up of 110 genes.  
 ISG15 Ubiquitin-Like Modifier (ISG15) was hypermethylated and overexpressed in our 
results and it functions closely with parkin. It behaves similarly to ubiquitin in that it covalently 
Table 20. Differentially methylated and differentially expressed genes in AD. 
Figure 15. Top DE and DMP by combined p-value in AD. 
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binds to target proteins (ISGylation) for biochemical modification and this mechanism is 
associated with JNK and NF-κB signal transduction and anti-viral responses. Parkin is ISGylated 
at two lysine residues by ISG15, mediated by HERC5 E3-ligase, promoting parkin’s E3 ligase 
activity and increasing its cytoprotective effect(Im et al.). ISG15 is activated by interferons alpha 
and beta and is a ubiquitin pathway antagonist that inhibits polyubiquitylation(Desai et al. 2018).  
 Peroxisomal Biogenesis Factor 10 (PEX10) is part of a collection of peroxisomal 
biogenesis proteins that import peroxisomal matrix proteins and are associated with autosomal 
recessive neurodegenerative disorders called peroxisome biogenesis disorders (PBD) on the 
Zellweger syndrome spectrum (PBD-ZSS). PEX10 mutations associated with this disease can 
result in a truncated isoform that lacks a c-terminal ring finger domain(Yik et al. 2009). PEX5 also 
arose as a gene of interest in our study, to be discussed in a later section. Seventeen HLA-B 
transcripts were among the top integrated hits, all hypomethylated and underexpressed. These 
genes were excluded from Table 21 to show additional genes of interest, though this highlights 
the important presence of T-cell activation and the immune response involved in this disease. 
 
Gene Transcript Probe P-Val Combined 
Methylation 
Fold 
Change 
Expression 
Beta 
Probe 
Position 
Relative 
to Island 
ISG15 ENST00000379389.4 cg12257384 4.34 x 10-6 -0.58 -0.79 Island 
ITM2C ENST00000335005.10 cg09972569 3.45 x 10-5 -0.73 -2.22 Island 
YIF1B ENST00000592694.5 cg11272232 6.40 x 10-5 -0.75 -2.15 OpenSea 
TREM1 ENST00000334475.10 cg26223899 2.21 x 10-4 -0.52 -0.80 N_Shelf 
PEX10 ENST00000447513.6 cg01947769 4.45 x 10-4 -0.53 -0.89 S_Shelf 
FKBP8 ENST00000597547.1 cg10011232 4.81 x 10-4 -0.53 -1.02 S_Shore 
Hypermethylated and Underexpressed 
SUMF2 ENST00000529457.1 cg10135877 2.44 x 10-5 1.45 -1.03 S_Shelf 
BAD ENST00000309032.7 cg21986781 3.35 x 10-5 0.54 -0.30 S_Shelf 
IGFBP4 ENST00000269593.4 cg05484949 2.08 x 10-4 0.53 -0.40 OpenSea 
LGALS9 ENST00000467111.5 cg26227119 4.36 x 10-4 0.29 -0.41 OpenSea 
C22orf34 ENST00000405854.5 cg19015962 6.32 x 10-4 0.78 -0.79 N_Shelf 
SIGIRR ENST00000528116.5 cg04663285 7.84 x 10-4 1.64 -0.71 Island 
MOB2 ENST00000531976.1 cg27373015 8.42 x 10-4 0.60 -0.20 OpenSea 
LGALS9 ENST00000486774.1 cg26227119 8.72 x 10-4 0.29 -0.26 OpenSea 
Hypomethylated and Overexpressed 
CD14 ENST00000498971.6 cg19008097 5.19 x 10-5 -0.54 1.60 S_Shore 
  79 
SUPT4H1 ENST00000581204.1 cg22481606 9.70 x 10-5 -0.52 1.56 Island 
ORC4 ENST00000392857.9 cg05172887 1.20 x 10-4 -0.57 1.72 OpenSea 
HSPH1 ENST00000602786.5 cg18351683 1.33 x 10-4 -0.99 1.19 OpenSea 
FCGR2A ENST00000461298.1 cg19240319 1.47 x 10-4 -0.71 0.59 Island 
FCGR2A ENST00000461298.1 cg00975746 1.61 x 10-4 -1.12 0.59 N_Shore 
PI4KB ENST00000368875.6 cg00107782 1.87 x 10-4 -0.51 1.06 Island 
ACTN1 ENST00000394419.8 cg27036347 4.34 x 10-4 -1.33 1.99 Island 
PDIA3 ENST00000455250.1 cg02953927 5.40 x 10-4 -0.85 1.35 Island 
CPSF2 ENST00000555244.1 cg09996633 8.35 x 10-4 -0.78 0.86 OpenSea 
SUMO1 ENST00000392244.7 cg08267047 8.42 x 10-4 -0.68 1.25 S_Shore 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 21. Differentially methylated and differentially expressed genes in PD. 
Figure 16. Top DE and DMP by combined p-value in PD. 
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Integrated Analysis: Combined p-values for Alzheimer’s & Parkinson’s Disease 
 SLC12A6 codes for a potassium/chloride cotransporter (KCC3). A mutation in this gene 
is known to cause hereditary motor and sensory neuropathy associated with agenesis of the 
corpus callosum (HMSN/ACC) which has developmental and neurodegenerative features(Dupré 
et al. 2006; Auer et al. 2016).  
 CUGBP Elav-Like Family Member 2 (CELF2) regulates alternative splicing and has been 
shown to repress inclusion of exon 10 in MAPT, tau protein, an aberration present in myotonic 
dystrophy type 1 (DM1) neuromuscular disease(Dhaenens et al. 2011).  
 POLD4 is the delta 4 subunit of DNA polymerase, involved in replication and repair. A 
study that used a chromosomal replication array found this gene to be underexpressed in 
schizophrenia versus controls, but found no difference when they looked at DNA methylation 
between the groups(Okazaki et al. 2016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Transcript & Probe 
AD P-Val 
Combined 
AD 
Methyl 
Fold 
Change 
AD 
Expr 
Beta 
PD P-Val 
Combined 
PD 
Methyl 
Fold 
Change 
PD 
Expr 
Beta 
Probe 
Position 
Relative 
to Island 
SLC12A6 ENST00000290209.9 cg27566947 2.38 x 10
-4 0.50 0.25 2.05 x 10-3 0.40 0.20 N_Shore 
POLD4 ENST00000312419.7 cg08662757 2.05 x 10
-4 -0.72 -0.26 7.85 x 10-5 -0.70 -0.28 Island 
POLD4 ENST00000312419.7 cg25753024 1.05 x 10
-4 -0.81 -0.26 1.82 x 10-5 -0.87 -0.28 Island 
MCTP2 ENST00000357742.8 cg21467108 1.10 x 10
-4 -0.42 0.34 9.30 x 10-4 -0.40 0.24 OpenSea 
SNX18 ENST00000381410.4 cg23001370 4.82 x 10
-4 -0.29 0.39 2.87 x 10-5 -0.40 0.37 S_Shore 
CELF2 ENST00000416382.6 cg11832281 3.72 x 10
-4 -0.43 0.49 1.29 x 10-3 -0.36 0.44 S_Shelf 
PRR5 ENST00000475850.1 cg23240895 2.85 x 10
-6 -0.42 -0.50 5.21 x 10-5 -0.42 -0.34 OpenSea 
POLRMT ENST00000587057.5 cg02707162 4.21 x 10
-4 -0.61 -0.39 1.02 x 10-3 -0.63 -0.31 N_Shore 
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Integrated Analysis: meQTL for Alzheimer’s Disease Patients. 
 Trans meQTLs showed a number of HLA, immunoglobulin and other immune response 
involved transcripts associated with distant probes. NF-κB signaling, regulation and RNA 
processing are among the top pathways after immune related functions. 
 Neuron Navigator 1 (NAV1; beta (effect = -0.04, FDR = 2.24 x 10-3) and RB Binding 
Protein 4, Chromatin Remodeling Factor (RBBP4; beta (effect = 1.01, FDR = 9.64 x 10-6) are both 
cis meQTLs. NAV1 is primarily expressed in the nervous system and is thought to play a role in 
growth cone dynamics of axons, dendrites, and migrating neurons(Martínez-López et al. 2005). 
 Tubulin Folding Cofactor D (TBCD) is a cis meQTL involved with post-translational 
protein folding. One CpG site is positively associated with three transcripts in our results (Table 
23). Upon upregulation of RBBP4 in DG of aged mice, novel object recognition and spatial 
reference memories improved comparably, independent of neurogenesis, to that of WT young 
mice(Pavlopoulos et al. 2013). 
CNOT2 is a marginal cis meQTL that is related to exonuclease activity pathway and mRNA 
processing. It induces ubiquitination of p62 (SQSTM1), a protein previously discussed in this 
work(Jeong et al. 2017). 
 Lactotransferrin (LTF; beta (effect = -105.89, FDR = 7.36 x 10-6) is an iron-binding 
glycoprotein that confers antioxidant effects and is a trans meQTL for AD. In addition to blood, it 
is expressed in the brain and is associated with aging and neurological disorders, including AD, 
as it has been found in neurofibrillary tangles and it may positively modulate the AKT pathway 
resulting in reduced AD pathology(Mohamed et al. 2019). 
Transcript ID Probe Gene FDR Beta (effect) 
CIS         
ENST00000587905 cg01299279 LDLRAD4 2.22 x 10-5 -0.60 
ENST00000588042 cg02278683 AC009303.2 8.95 x 10-3 -0.28 
ENST00000430015 cg12468255 NAV1 2.24 x 10-3 -0.04 
ENST00000571796 cg00960700 TBCD 6.18 x 10-3 40.00 
Table 22. Differentially methylated and differentially expressed genes in AD and PD. 
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ENST00000574886 cg00960700 TBCD 6.77 x 10-4 36.38 
ENST00000300784 cg00960700 FN3K 7.92 x 10-3 19.57 
ENST00000592411 cg23784912 ZNF519 5.87 x 10-3 4.26 
ENST00000570734 cg00960700 FN3K 4.74 x 10-2 4.19 
ENST00000531983 cg17339202 RBBP4 9.64 x 10-6 1.01 
ENST00000382149 cg15401952 KCNIP4 2.38 x 10-2 0.33 
ENST00000525171 cg14304817 NAALAD2 9.64 x 10-6 0.11 
TRANS         
ENST00000421349 cg02553872 HLA-B 1.04 x 10-5 -4095.98 
ENST00000415187 cg21120951 TMSB4XP6 9.19 x 10-6 -1745.62 
ENST00000466304 cg02553872 HLA-B 3.16 x 10-6 -314.34 
ENST00000466340 cg02553872 SELL 1.04 x 10-5 -234.83 
ENST00000476677 cg03184194 HLA-DPB1 1.04 x 10-5 -229.25 
ENST00000638375 cg18626958 HLA-A 3.35 x 10-6 -124.12 
ENST00000399500 cg18626958 HLA-DPB1 2.96 x 10-6 -111.09 
ENST00000492796 cg02553872 CDC42SE1 9.19 x 10-6 -107.60 
ENST00000426532 cg10814415 LTF 7.36 x 10-6 -105.89 
ENST00000384161 cg22620689 RNU6-48P 1.04 x 10-5 -75.51 
ENST00000487685 cg03184194 HLA-DPB1 1.04 x 10-5 -70.63 
ENST00000395388 cg00960700 HLA-DRA 9.19 x 10-6 5426.51 
ENST00000384161 cg23784912 RNU6-48P 1.04 x 10-5 321.31 
ENST00000482769 cg14304817 IGKV2-28 1.04 x 10-5 228.80 
ENST00000633682 cg14304817 IGKV2-28 1.04 x 10-5 228.80 
ENST00000613056, 
ENST00000614745 cg23784912 MBOAT7 1.05 x 10
-5 212.19 
ENST00000530802 cg00960700 TCIRG1 9.19 x 10-6 115.48 
ENST00000466602 cg00960700 CYP27A1 9.19 x 10-6 100.45 
ENST00000636081 cg23784912 EHMT1 1.04 x 10-5 89.95 
ENST00000516601 cg00960700 RNU5B-3P 9.19 x 10-6 73.67 
Transcript ID Probe Gene P-value FDR Beta (effect) 
CIS 
ENST00000595791 cg22266001 MAG 5.18 x 10-5 2.49 x 10-1 4.16 
ENST00000551661 cg19390271 CNOT2 6.75 x 10-5 2.97 x 10-1 -3.34 
ENST00000550641 cg19390271 CNOT2 7.72 x 10-5 3.06 x 10-1 -2.12 
ENST00000574975 cg00960700 TBCD 1.30 x 10-5 8.41 x 10-2 20.19 
 
 
 
 
 
Table 23. Methylation quantitative trait loci (meQTLs) in AD. 
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Integrated Analysis: meQTL for Parkinson’s Disease Patients. 
 Gene set enrichment analysis showed associations between DMPs and expression 
changes in pathways related to telomere regulation and chromatin organization for genes in cis 
and protein-DNA complexing and transcription in trans. As with the AD cases, trans meQTLs for 
PD reflect an immune response with a relatively high number of HLA and other immune involved 
transcripts associated with distant probes. Aside from the prominent presence HLA and 
immunoglobulin meQTLs, genes involved in neurotrophin signaling and glycogen metabolic 
processes made up the next most prominent pathways for this set. 
 Colony Stimulating Factor 3 Receptor (CSF3R; beta (effect = -105.89, FDR = 7.36 x 10-6) 
is a trans meQTL for PD. CSF1R is necessary for microglia survival(Yang et al. 2018). Additional 
cis meQTLs of interest are a block involved in similar functions. Histone Deacetylase 10 
(HDAC10), Nudix Hydrolase 21 (NUDT21), Protein Kinase N1 (PKN1), and Nuclear Receptor 
Corepressor 2 (NCOR2) are involved in histone deacetylase binding and ERCC Excision Repair 
Figure 17. Representative plot of a cis meQTL in AD. 
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1, Endonuclease Non-Catalytic Subunit (ERCC1) is involved with chromosome organization. 
NCOR2 was also a gene of interest from the second chapter presented in this dissertation. 
 
Transcript ID Probe Gene FDR Beta (effect) 
CIS         
ENST00000483148 cg14288209 APTX 2.95 x 10-2 -77.24 
ENST00000586305 cg18480790 RASGRP4 4.40 x 10-2 -47.56 
ENST00000441983 cg02494999 TRAPPC12 2.61 x 10-2 -29.64 
ENST00000454664 cg13777287 CNKSR3 3.94 x 10-3 -0.21 
ENST00000525171 cg14304817 NAALAD2 2.08 x 10-5 0.11 
ENST00000575679 cg02214414 FLYWCH1 8.23 x 10-3 7.00 x 10-8 
TRANS         
ENST00000638576 cg12376805 HLA-A 1.35 x 10-6 -132.23 
ENST00000391737 cg04422985 LILRA2 1.03 x 10-7 -121.07 
ENST00000412634 cg04422985 HLA-DRB1 6.24 x 10-7 -76.77 
ENST00000373106 cg24430871 CSF3R 2.24 x 10-7 -71.42 
ENST00000587728 cg26796043 ADGRE5 6.59 x 10-6 -59.11 
ENST00000373106 cg26796043 CSF3R 6.39 x 10-8 -56.27 
ENST00000463148 cg26868306 HLA-A 1.69 x 10-5 -51.25 
ENST00000490676 cg15471402 HLA-B 4.69 x 10-6 1311.16 
ENST00000390283 cg11382477 IGLV8-61 7.64 x 10-6 838.34 
ENST00000399088 cg15471402 HLA-DQB1 2.48 x 10-5 297.73 
ENST00000412634 cg23502778 HLA-DRB1 2.43 x 10-5 155.28 
ENST00000565375 cg15471402 HLA-V 2.15 x 10-11 97.30 
ENST00000430299 cg15471402 HLA-B 1.31 x 10-10 84.96 
ENST00000391738 cg23502778 LILRA2 2.54 x 10-5 83.04 
ENST00000639848 cg15471402 HLA-B 5.79 x 10-8 81.13 
ENST00000633660 cg15471402 TRBJ2-7 1.77 x 10-6 78.22 
ENST00000632846 cg11382477 IGHV3-66 1.26 x 10-6 66.85 
ENST00000625402 cg04865110 SCARNA4 2.76 x 10-6 59.85 
ENST00000384986 cg04865110 MIR623 2.76 x 10-6 57.15 
ENST00000547013 cg15471402 TMBIM6 2.92 x 10-6 54.91 
Transcript ID Probe Gene P-value FDR Beta (effect) 
CIS  
ENST00000436302 cg05351601 AGBL3 1.31 x 10-5 5.71 x 10-2 7.81 
ENST00000592410 cg26322788 ERCC1 1.71 x 10-5 5.73 x 10-2 4.56 
ENST00000497952 cg23762037 HDAC10 2.11 x 10-5 6.06 x 10-2 -810.96 
ENST00000405201 cg16713625 NCOR2 1.26 x 10-4 2.27 x 10-1 -22.82 
ENST00000563362 cg11323230 NUDT21 2.30 x 10-4 2.75 x 10-1 -171.57 
ENST00000591461 cg20468939 PKN1 8.66 x 10-4 5.92 x 10-1 -189.66 
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Integrated Analysis: meQTLs for Alzheimer’s & Parkinson’s Disease. 
 NAALAD2 is part of the transferrin receptor family involved in iron transfer. It cleaves 
NAAG, a neuropeptide expressed in the peripheral and central nervous systems, and 
dysregulation of this system has been suggested to contribute to several neurological disorders 
through altered glutamate regulation(Pangalos et al. 1999). It is the only cis acting meQTL 
present for both AD and PD in our results. 
 Two CpG sites shared by AD and PD have trans acting associations with a variety of 
gene transcripts. Both diseases produced trans meQTLs for a relatively large number of 
noncoding RNA species, including pseudogenes and miRNAs.  
 
 
Table 24. Methylation quantitative trait loci (meQTLs) in PD. 
Figure 18. Representative plot of a cis meQTL in PD 
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Transcript Probe Gene AD FDR 
AD 
Beta 
(effect) 
PD FDR 
PD 
Beta 
(effect) 
CIS 
ENST00000525171 cg14304817 NAALAD2 9.64 x 10-6 0.11 2.08 x 10-5 0.11 
TRANS 
ENST00000632846 cg14304817 IGHV3-66 2.94 x 10-5 35.60 1.98 x 10-6 34.99 
ENST00000390283 cg14304817 IGLV8-61 8.81 x 10-6 455.36 4.54 x 10-6 441.86 
ENST00000383411 cg17339202 MPIG6B 1.22 x 10-5 3.88 1.70 x 10-5 3.79 
ENST00000525902 cg17339202 CTNND1 1.49 x 10-5 7.28 2.36 x 10-5 7.09 
ENST00000432428 cg14304817 FLOT1 1.40 x 10-5 18.71 2.46 x 10-5 18.19 
ENST00000362918 cg14304817 RNY3P2 1.72 x 10-5 9.58 2.55 x 10-5 9.31 
ENST00000368330 cg14304817 YY1AP1 1.72 x 10-5 5.38 2.55 x 10-5 5.23 
ENST00000385017 cg14304817 MIR553 1.72 x 10-5 6.36 2.55 x 10-5 6.18 
ENST00000385302 cg14304817 MIR320A 1.72 x 10-5 5.44 2.55 x 10-5 5.29 
ENST00000408135 cg14304817 MIR1292 1.72 x 10-5 6.54 2.55 x 10-5 6.35 
ENST00000408346 cg14304817 MIR1237 1.72 x 10-5 9.58 2.55 x 10-5 9.31 
ENST00000408874 cg14304817 MIR548H2 1.72 x 10-5 5.75 2.55 x 10-5 5.59 
ENST00000411464 cg14304817 MRPL55 1.72 x 10-5 3.37 2.55 x 10-5 3.28 
ENST00000458862 cg14304817 SNORA47 1.72 x 10-5 8.97 2.55 x 10-5 8.72 
ENST00000459332 cg14304817 SNORD108 1.72 x 10-5 5.97 2.55 x 10-5 5.80 
ENST00000466367 cg14304817 ARRDC1 1.72 x 10-5 3.69 2.55 x 10-5 3.59 
ENST00000521949 cg14304817 NIPAL2 1.72 x 10-5 6.75 2.55 x 10-5 6.56 
ENST00000533417 cg14304817 CD81 1.72 x 10-5 3.72 2.55 x 10-5 3.61 
ENST00000579005 cg14304817 SAP30BP 1.72 x 10-5 5.12 2.55 x 10-5 4.98 
ENST00000582739 cg14304817 MIR548Y 1.72 x 10-5 11.69 2.55 x 10-5 11.36 
ENST00000584654 cg14304817 MIR3116-1 1.72 x 10-5 5.82 2.55 x 10-5 5.66 
ENST00000620884 cg14304817 MIR6837 1.72 x 10-5 3.36 2.55 x 10-5 3.27 
ENST00000637097 cg14304817 SMARCA2 1.72 x 10-5 8.80 2.55 x 10-5 8.56 
ENST00000625868 cg14304817 SERF1A 1.75 x 10-5 3.61 2.55 x 10-5 3.51 
ENST00000461736, 
ENST00000488182 cg17339202 ABHD16A 2.59 x 10
-5 4.79 3.15 x 10-5 4.67 
ENST00000479622, 
ENST00000481723 cg17339202 ABHD16A 2.53 x 10
-5 6.83 3.15 x 10-5 6.66 
ENST00000415983 cg17339202 HLA-U 2.84 x 10-5 5.07 3.15 x 10-5 4.95 
ENST00000616820 cg17339202 LILRB4 2.84 x 10-5 5.90 3.15 x 10-5 5.76 
 
 
 
 
Table 25. Methylation quantitative trait loci (meQTLs) in AD and PD. 
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Integrated Analysis: FEM for Alzheimer’s Disease Patients 
 Functional epigenetic modules identifies gene modules in protein-protein interaction 
networks associated with differentially methylated and differentially expressed loci. The FEM 
networks in AD are driven by five genes:  CSGALNACT1 (p = 0.00), PNPLA2 (p = 5.00 x 10-3), 
PILRA (p = 1.40 x 10-2), AGTRAP (p = 3.90 x 10-2), and LPPR2 (p = 4.10 x 10-2).   
 Paired Immunoglobin Like Type 2 Receptor Alpha (PILRA) is a cell surface receptor 
expressed on innate immune cells, including microglia, that inhibits signal transduction through 
recruitment of phosphatases for control by dephosphorylation. Rathore at al. describe a missense 
variant in PILRA that may confer protection from a known AD risk locus (7q21 locus (rs1476679)) 
through reduced ligand interaction and subsequent increased microglia activation(Rathore et al. 
2018). 
Integrated Analysis: FEM for Parkinson’s Disease Patients 
 FEM networks for PD produced the following gene modules:  PEX5 (p = 2.00 x 10-3), 
RAB3IP (p = 5.00 x 10-3), PPP4R2 (p = 7.00 x 10-3), MOB4 (p = 1.30 x 10-2), CSGALNACT1 (p = 
1.70 x 10-2), SLC4A7 (p = 2.60 x 10-2), and KCNJ11 (p = 2.60 x 10-2). 
 Peroxisomal Biogenesis Factor 5 (PEX5) binds to PTS1-type peroxisomal targeting 
signal and is essential for peroxisomal protein import. PEX5 has been studied for its potential role 
in PD from the context of peroxisome biogenesis disorders and the effect of oxidative stress on 
alpha-synuclein(Yakunin et al. 2010). PEX10 also revealed itself in the present study as a gene 
that was both differentially methylated and expressed, as well as alternatively spliced (results not 
shown).  
Integrated Analysis: FEM for Alzheimer’s & Parkinson’s Disease 
 Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1 (CSGALNACT1) is an enzyme 
that functions to elongate chondroitin sulfate chains and is associated with the progression of 
multiple sclerosis. This gene is the driver of a module in both AD and PD. 
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Gene (Seed) Module Size P-value Genes in Module 
AD modules 
CSGALNACT1 11 0.000 
CSGALNACT1, TMEM214, SLC30A1, TMUB1, 
CSGALNACT2, TMX4, KIAA1467, GPRC5B, 
B3GALNT1, SLC8A3, SLC8A2 
PNPLA2 6 0.005 PNPLA2, SERPINF1, PHYHIP, ABHD5, FAM131A, PLIN1 
PILRA 6 0.014 PILRA, SAR1B, LRRTM4, DNPH1, B4GALNT3, B4GALNT4 
AGTRAP 15 0.039 
AGTRAP, TMEM14B, NDRG4, C12orf10, GAD2, 
ZNF391, PCTP, SYT16, NFU1, PITPNC1, ACSF2, 
TBRG4, MIEF1, GAD1, SYT14 
LPPR2 6 0.041 LPPR2, C9orf40, PCDH9, DNAJC12, UQCC2, METAP1 
PD modules 
PEX5 24 0.002 
PEX5, PEX7, CAPRIN2, RANBP6, TOMM7, 
ACOT2, LONP2, GDPD5, HMGCL, EPHX2, 
PEX10, ZADH2, ECI2, S100A6, PEX2, TYSND1, 
PEX12, ZNF772, ACOX3, MLYCD, ACOX2, 
TM6SF1, MS4A7, PEX5L 
RAB3IP 5 0.005 RAB3IP, CCDC146, FAM124A, RAB3IL1, RAB3D 
PPP4R2 6 0.007 PPP4R2, WDR55, LCMT1, FAM133B, AMPD2, CUTA 
MOB4 18 0.013 
MOB4, STRIP1, STRN, STK25, ZRANB1, PTPRS, 
EGLN2, KIDINS220, SLMAP, CTTNBP2NL, 
SIKE1, STRIP2, PLEKHM1, CTTNBP2, RASSF3, 
RUFY3, KIAA1456, ASH1L 
CSGALNACT1 7 0.017 CSGALNACT1, ARFGEF1, SLC30A1, CSGALNACT2, TMX4, KIAA1467, GPRC5B 
SLC4A7 11 0.026 SLC4A7, SLC4A4, GDE1, TEX29, STEAP3, CA4, SLC6A15, CA2, SLC4A8, PTS, FNDC5 
KCNJ11 8 0.026 KCNJ11, KCNJ8, FAM63B, ABCC8, CYP2J2, SLC2A8, XXYLT1, NCR3LG1 
 
 
 
 
 
 
Table 26. Functional epigenetic modules for AD and PD. Protein-protein interaction sub-
networks identified as differentially methylated (promoter region) and differentially expressed, 
with an inverse relationship. 
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OVERLAPPING RESULTS ACROSS STUDIES 
 HSPB1 was overexpressed in PDD brain tissue (Chapter 1) and underexpressed in PD 
blood (Chapter 3). Five of the 7 significant overlapping expression hits across these two studies 
were hemoglobin (Hb) subunit (α or β) genes (HBA2 or HBB), all underexpressed in both tissue 
types. Overlapping expression results are presented in Table 27. 
 There were about 30 differentially methylated positions in common between our chapter 
2 and chapter 3 studies (Table 28). Histone deacetylase activity and Notch pathway signaling are 
the most prominent pathways in this list.  
 
Transcript ID Gene Name 
Fold 
Change 
(log2) 
PD Brain 
adjP-val 
PD Brain 
beta_DE 
PD Blood 
pval 
PD Blood 
PD brain and PD blood overlapping results  
ENST00000347063.8 RNF175 -0.77 8.08 x 10-3 0.46 3.23 x 10-4 
ENST00000377103.2 THBD 1.11 1.47 x 10-3 0.69 3.79 x 10-4 
ENST00000482949.5 LCK 1.57 3.84 x 10-3 2.02 3.09 x 10-3 
ENST00000246006.4 CD93 1.56 3.24 x 10-5 0.39 6.97 x 10-3 
ENST00000334475.10 TREM1 1.33 3.68 x 10-3 -0.80 8.12 x 10-3 
ENST00000552456.1 P2RX5 -1.02 3.34 x 10-3 -0.56 9.22 x 10-3 
ENST00000497360.5 SLC4A1 -1.74 1.12 x 10-4 -0.82 9.80 x 10-3 
PDD brain and PD blood overlapping results  
ENST00000429938.1 HSPB1 1.62 1.06 x 10-4 -0.43 4.69 x 10-3 
ENST00000475226.1 HBB -1.33 3.29 x 10-3 -0.88 1.17 x 10-2 
ENST00000397806.1 HBA2 -1.34 1.29 x 10-3 -0.84 1.42 x 10-2 
ENST00000482565.1 HBA2 -1.34 1.29 x 10-3 -0.74 1.99 x 10-2 
ENST00000485743.1 HBB -1.33 3.29 x 10-3 -0.79 2.00 x 10-2 
ENST00000387372.1 MT-TQ 2.20 2.17 x 10-5 -0.66 2.80 x 10-2 
ENST00000633227.1 HBB -1.33 3.29 x 10-3 -0.78 2.94 x 10-2 
 
Figure 19. Functional epigenetic modules. (A) PILRA, in AD, is a hypermethylated and 
overexpressed gene driving this module and (B) PEX5, in PD, is hypomethylated connected 
with several overexpressed genes, and one closely related gene that is hypermethylated and 
overexpressed (PEX5L). 
Table 27. Differentially expressed genes shared across PD or PDD brain (chapter 1), and 
PD blood (chapter 3). 
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Table 28. Differentially methylated positions shared across chapter 2 and chapter 3 studies 
in PD blood. 
Probe Gene ID 
Study 3 
Fold 
Change 
(log2) 
Study 3 
P.Value 
Cross-sectional (S2 DMPs – Table 6) 
cg02938407 EXOC3L4 -0.27 1.68 x 10-3 
cg10800369 LMO3 -0.84 2.16 x 10-3 
cg26354439 DYNC1H1 -0.28 2.23 x 10-3 
cg04347164 ZFR2 -0.27 3.05 x 10-3 
cg04154697 ZFR2 -0.30 3.09 x 10-3 
cg18253473 DYNC1H1 -0.23 3.73 x 10-3 
cg27109672 DLK1 -0.26 4.82 x 10-3 
cg03578918 EXOC3L4 -0.29 4.97 x 10-3 
cg25285743 LMO3 0.80 5.31 x 10-3 
cg03163184 LMO3 -0.62 6.35 x 10-3 
cg22382058 ZFR2 -0.28 7.72 x 10-3 
Longitudinal (S2 DMPs – Table 8) 
cg03508817 HDAC4 -0.36 2.52 x 10-3 
cg14120784 GTF2I -0.39 2.57 x 10-3 
cg16713625 NCOR2 -0.74 3.83 x 10-3 
cg13956095 METRNL -0.55 5.13 x 10-3 
cg20105848 KRTAP5 -0.43 5.31 x 10-3 
cg07055330 HDAC4 0.31 5.49 x 10-3 
cg01390479 HDAC4 -0.24 5.57 x 10-3 
cg01764079 ZNF623 -0.22 6.10 x 10-3 
cg26451769 METRNL -0.24 6.99 x 10-3 
cg21248987 SDK1 -0.93 7.49 x 10-3 
cg22166325 EDC3 -0.24 7.91 x 10-3 
cg02001099 HDAC4 0.72 8.00 x 10-3 
cg17647904 NCOR2 -0.29 8.29 x 10-3 
cg24978805 SDK1 -0.24 8.39 x 10-3 
cg16114651 GTF2I -0.35 8.41 x 10-3 
cg18493115 KRTAP5 1.40 8.43 x 10-3 
cg06228737 ABAT 0.37 8.70 x 10-3 
cg05865340 HDAC4 -0.51 8.81 x 10-3 
cg21831587 GTF2I -1.05 9.07 x 10-3 
cg02329576 SDK1 -0.44 9.72 x 10-3 
 
Probe Gene ID 
Study 3 
Fold 
Change 
(log2) 
Study 3 
P.Value 
Longitudinal, with medication (S2 DMPs – Table 9) 
cg26247309 PDGFRB -0.42 2.11 x 10-3 
cg03508817 HDAC4 -0.36 2.52 x 10-3 
cg14120784 GTF2I -0.39 2.57 x 10-3 
cg10543797 NADK 0.31 3.12 x 10-3 
cg07055330 HDAC7 0.31 5.49 x 10-3 
cg01390479 HDAC8 -0.24 5.57 x 10-3 
cg01764079 ZNF623 -0.22 6.10 x 10-3 
cg02001099 HDAC5 0.72 8.00 x 10-3 
cg16114651 GTF2I -0.35 8.41 x 10-3 
cg05865340 HDAC6 -0.51 8.81 x 10-3 
cg21831587 GTF2I -1.05 9.07 x 10-3 
Longitudinal, No medication (S2 DMPs – Table 10) 
cg17087669 MAPK13 -0.36 1.81 x 10-3 
cg02711976 KIAA0319 -0.35 3.56 x 10-3 
cg17211404 PLA2G7 -0.45 4.18 x 10-3 
cg18865832 PCDHB16 0.76 7.68 x 10-3 
cg14983698 CEP70 -0.24 9.25 x 10-3 
cg08908843 SECISBP2 -0.20 9.93 x 10-3 
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DISCUSSION 
 Many known AD and PD associated pathways continually arose in our datasets. This is 
important to reinforce certain known, or suspected mechanisms associated with disease, but we 
also presented additional targets to be exploited for potential therapeutic applications which 
would follow the necessary functional validations. The other important aspect of thematic gene 
and pathway hits is the prospect for biomarker development, especially for hits that are present in 
the three separate studies, including across tissues, presented here. 
 Our results showed links to two different HERC E3 ligase proteins, HERC5 and HERC2, 
associated with known PD susceptibility genes, parkin and LRRK2, respectively. These results 
highlighted the ubiquitin pathway and Notch signaling, both good targets for PD research 
extending into earlier disease stages. PKA, PI3K/AKT, and JAK/STAT are additional pathways of 
particular continued interest in both AD and PD. Mechanisms that affect transcription regulation 
and chromatin organization are relevant to our interests in gene expression and regulation via 
DNA methylation, but there is also a strong immune response presence is these diseases, 
particularly evident in the HLA and immunoglobulin hits in both brain and blood tissues. Active 
immune-related pathways is not a new finding, but it supports that this facet of neurological 
disorders must remain a focus of study and cannot be dismissed as a side-effect of inevitable 
neuroinflammation owing to some other causal early life insult to the nervous system. 
Differential Expression in AD & PD.  
 The presence of NUMB, APP and UPP1 together implicates the involvement of γ-
secretase activity in both diseases. Another common thread among the genes differentially 
expressed in PD and AD is protein degradation, whether that be a contributor to pathology or a 
consequence thereof. 
Integrated Analysis: Combined p-values for AD & PD.  
 The unifying theme in the integrated PD analysis, combining differentially methylated 
positions and differentially expressed genes, is ubiquitination and the mechanistically related 
process of mitophagy. These pathways are widely known for their involvement in aberrant 
functioning within neurodegenerative disease systems, like ALS and AD. 
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Overlapping Results Across Studies. 
 Overexpressed HSPBs. Small heat shock proteins (HSPBs) are a common focus within 
PD research for their involvement in protein folding. HSPB1, along with several other HSPBs, 
was found to be a potent aggregation suppressor of mutated PARK2 isoform (C289G), a 
prevalent cause of juvenile onset PD(Minoia et al. 2014). The authors of that study suggested 
that HSPB1 aggregation interference was involved with an autophagy or protein degradation 
related function. 
 Underexpressed hemoglobin (Hb) subunit (α or β) genes (HBA2 or HBB). HBA2 and 
HBB are preferentially expressed in A9 dopamine (DA) neurons of the substantia nigra (the 
primary site associated with PD pathology) over A10 DA neurons of the adjacent ventral 
tegmental area (not associated with PD pathology). Codrich et al. suggest Hb related 
impairments could be related to several functions already tied to PD, including mitochondrial 
function and autophagy impairment. Among their findings, they reported reduced DA with Hb 
overexpression in vivo; additionally, they cited down-regulation of both Hb subunits in DA neurons 
of rotenone treated rats, but up-regulation in PD brains(Codrich et al. 2017). In line with our 
underexpressed results, Ferrer et al. reported underexpression of HBB and HBA2 in the vast 
majority of neurons containing hyper-phosphorylated tau deposits in the frontal cortex and 
hippocampus of AD brains, which is also relevant to the late stages of PD pathology, and PDD, 
where tau pathology is prevalent. They also found that Hb was barely present in about 80% of DA 
substantia nigra neurons that contained α-synuclein inclusions(Ferrer et al. 2011a). Also of 
interest in this overlapping results list were Mitochondrially Encoded tRNA Glutamine (MT-TQ) 
and AD-associated Triggering Receptor Expressed On Myeloid Cells (TREM1), overexpressed in 
PDD or PD brain, respectively, and underexpressed in PD blood. 
 Differential methylation related to HDAC activity and Notch pathway signaling. 
Previously discussed, NUMB was overexpressed in our AD and PD blood differential expression 
results, and NCOR2 was a hit from the longitudinal PD study in chapter 2, which is also a DMP in 
the present study. Notch signaling affects cell differentiation and development, including neurite 
outgrowth, synaptic plasticity and olfactory functions in the adult brain. Imai et al. reported that 
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LRRK2, a key PD susceptibility gene, modulates Notch signaling along its endocytic pathway via 
the LRRK2-associated proteins, NEURL4 and HERC2(Imai et al. 2015). 
 
CONCLUSIONS 
 These studies were initiated with RNAseq to study gene expression in PD, then the query 
schema was elevated by incorporating epigenetic, and other expression modifiers, to ultimately 
join these data types into “multi-omic” analyses, allowing for a more nuanced and powerful 
characterization of the disease state.  
 In my first chapter, I compared gene expression levels across PD, PDD, and control brain 
tissues. I again applied this approach in chapter 3 to blood samples from PD, AD, and controls, 
with the added addition of DNA methylation measurements in the same patients.  
 Chapter 1 results revealed new, and some expected, molecular markers of progression 
from PD to PDD and we highlighted the largest differences when compared to healthy controls. 
Importantly, we found genes that may be more indicative of the advanced pathological state when 
focusing on the PD vs. PDD comparison. In particular, PENK may be of interest as a marker of 
disease progression, especially since this gene was also in a differentially methylated region, 
shown in chapter 2. In our alternative splicing analysis we validated a retained intron event for 
PDD patients in a gene called RELA, which suggested perturbed signaling within the immune 
response NFκB pathway by influencing nuclear localization capabilities. We also identified an 
exon skip event in SRRM1, which could impact proper splicing in PD. 
 In chapter 3 I presented integrated analyses of differential gene expression and 
differential methylation datasets to leverage the full potential of collecting data that represents 
these highly interconnected biological processes. The individual datasets showing methylation 
sites and genes, unique to PD or AD, yielded some interesting results alone. However, 
intersecting these data types pulled out possibly the most functionally relevant genes, since they 
were not only differentially expressed but also more likely to be under the influence of disease-
specific DNA methylation changes. In addition to finding unique, disease-specific changes, I 
showed genes from each chapter 3 analysis that were shared between AD and PD. Combining 
  95 
the top hits from those lists offers additional targets for studies of dysregulation in 
neurodegeneration and subsequent dementias. 
 Chapter 2 provided a solid preliminary step toward more extensive longitudinal tracking of 
DNA methylation changes in the progression of PD. Even with only two time points, we identified 
several genes of interest that are potential biomarker candidates. Three genes in particular were 
bolstered by results in chapter 3. NCOR2, DLK1, and HDAC4 were top hits in both studies; five 
total HDACs came up as shared hits across both chapters which may be indicative of dynamic 
regulation by DNA methylation of these sites late in the disease stage. Four of them arose 
specifically from the comparison of medicated PD patients vs. controls in study 2, which 
implicates this class of molecules as influential in the beneficial medication effects conferred upon 
PD patients. It is also feasible to consider then, that perhaps these HDACs target some early 
sites of molecular pathology making them a class to be tracked in a future longitudinal study over 
many years.  NCOR2 and DLK1 hits across studies suggests that these genes are also good 
candidates for PD biomarkers, and their involvement in NOTCH signaling provides a target 
pathway for functional validation studies as well. 
 Taken together, this collection of work has added more information to the field about the 
importance of splicing in Parkinson’s disease brains, and I provided additional evidence that 
some changes in the brain are reflected in the blood. We also uncovered DNA methylation hits 
from two different blood studies that might be good PD biomarkers, for diagnosis, for progression 
of the disease, and for monitoring of medication efficacy. Additional work is needed to develop 
these candidates into a true methylation biomarker panel that can be clinically tested, but I have 
narrowed these datasets down to at least, but not limited to, five potential genes as a starting 
point:  PENK, CYP2E1, NCOR2, DLK1, and HDAC4. 
 
FUTURE DIRECTIONS 
 The foundational work presented here marks an important starting point for further PD 
biomarker development using signature DNA methylation changes as the basis for disease 
detection. In order to move closer to disease prediction in the pre-motor stage and strengthen our 
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candidate markers, we should expand our profiling to include additional PD subsets to obtain a 
more complete characterization along the PD spectrum. 
 First, the chapter 2 longitudinal study can essentially be lengthened to cover more years 
of progression, and also include in an early-onset cohort (<60 years old), aiming for ten blood 
collections from each patient over ten years, for example. Alternatively, track patients for 5 years 
and collect blood samples every six months. The latter timeline and collection points would be 
more beneficial to clinicians interested in tracking medication efficacy, and would also give a 
slightly better idea of the dynamic variability in methylation status across 6-month periods. In 
either case, track the defined set of proposed markers across groups, including as many 
medication naïve patients as possible for a separate comparison. Changes in the biomarker 
panel would be monitored with yearly or semiannual progression to look for associations in 
methylation changes, near NCOR2, HDAC4, and others, with rate of progression. We would also 
include comparisons of early-onset cases with late-onset ones, as there may be distinct 
differences between these PD subsets that lead to divergent biomarker panels. Conversely, it 
would be just as important to look for a set of target genes that consistently arise across PD 
subsets, which would amount to the most general PD biomarker that is still distinct from healthy 
controls. Since I showed preliminary evidence of PD medication effects on DNA methylation 
status in chapter 2, this follow-up study should again compare patients taking medication to 
patients not taking medication, and we would look for normalizing effects on methylation status 
over time in the medicated set.  
 In addition to tracking of the aforementioned gene regions, I would consider tracking a 
class or family of molecules (e.g., ten additional genes) that represented a relatively high 
proportion of our top gene hits, like HDACs or include additional NOTCH pathway genes in the 
panel. If it happens that we hit on a couple pathways that are highly active late in the disease, it 
may be more promising to also detect those changes much earlier in the disease state.  
 Second, we could target a cohort of high risk patients for yearly tracking as well. For 
example, REM sleep behavior disorder (RBD) is a primary prodromal PD risk factor that 
represents a good early detection study cohort. PD patients are diagnosed on average in their 
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early 60s, and RBD patients in the range of 50-60 years old. Therefore, it would be useful to track 
an RBD cohort beginning at least several years before the average conversion age to PD with 
continued monitoring several years after any PD diagnoses. To find the best disease markers 
spanning pre-motor to late-stage PD, the resulting hits would be compared to RBD patients who 
did not convert to PD, and to hits that arise in studies of already diagnosed PD patients. This 
design would do well with a five year split before and after conversion, expanding the total 
duration to an earlier starting point as patient availability and funding permit. 
 Finally, the target genes previously listed may also be good candidates for functional 
validations. I would design experiments in an effort to uncover their specific molecular roles using 
in vitro and in vivo models of Parkinson’s disease. Validation studies could lend to improved 
biomarker specificity, in terms of gained knowledge of pathway functionality and DNA methylation 
effects, and provide solid leads for clinical trial work. 
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